Published by CertaPeptides. For research purposes only.

The hypothalamus contains a small number of neuron populations that set the tempo of reproductive neuroendocrine signalling. Two peptide systems come up again and again in that literature: kisspeptin, acting through the receptor KISS1R (also called GPR54), and oxytocin, acting through the oxytocin receptor (OXTR). Both are G protein-coupled receptor (GPCR) systems, both are expressed in hypothalamic circuits, and both have become standard tools for probing how peptide signals control neuronal excitability and hormone release in cell and animal models.

This guide gives an overview of the research category behind our gonadotropic research peptides. It covers the pathway as a field of study, how kisspeptin-10 and oxytocin are used as receptor probes, where the two systems meet, and the general laboratory practices that apply to lyophilised peptides of this kind. For a deeper discussion of kisspeptin specifically, see our dedicated article on kisspeptin-10 in reproductive neuroendocrine research.

What is the gonadotropic pathway as a research field?

In vertebrate physiology, the term “gonadotropic pathway” describes the chain of signals that links the brain to the gonads, often called the hypothalamic-pituitary-gonadal (HPG) axis. At its top sits a scattered population of hypothalamic neurons that secrete gonadotropin-releasing hormone (GnRH) into the portal blood of the median eminence. GnRH acts on pituitary gonadotrope cells, which in turn release luteinising hormone (LH) and follicle-stimulating hormone (FSH). In laboratory work these endogenous hormones are mostly measured as read-outs: a rise or fall in LH in an animal model is used as a proxy for what GnRH neurons are doing.

The research questions in this field are largely neurobiological. How do GnRH neurons generate pulses? Which upstream neurons drive them? How do steroid hormones feed back onto the hypothalamus? Which receptors and second-messenger pathways translate a peptide signal into a change in firing? Answering these questions needs selective ligands that act on defined receptors, which is where research peptides such as kisspeptin-10 and oxytocin come in.

Why GPCR signalling matters here

Most of the neuropeptide receptors in this system belong to the class A (rhodopsin-like) GPCR family. When an agonist binds, the receptor changes shape and engages heterotrimeric G proteins. For both KISS1R and OXTR, the main coupling studied is to Gq/11 proteins, which activate phospholipase C-beta (PLC-beta). PLC-beta hydrolyses the membrane lipid PIP2 into inositol trisphosphate (IP3) and diacylglycerol. IP3 releases calcium from intracellular stores, and diacylglycerol activates protein kinase C. Downstream, research groups track calcium transients, MAP kinase phosphorylation (ERK1/2, p38) and changes in membrane potential as measurable outputs.

Because these read-outs can be measured in transfected cell lines, in brain slices and in whole animals, the same ligand can be followed from receptor binding through to circuit-level effects. That continuity is a large part of why kisspeptin and oxytocin are so widely used as research tools.

Kisspeptin-10: a KISS1R/GPR54 agonist research tool

This section is a short summary. Our kisspeptin-10 reference article covers receptor signalling and HPG axis research in more depth.

Discovery and receptor pharmacology

Kisspeptins were identified in 2001 by two independent groups as the endogenous ligands of the then-orphan receptor GPR54. Ohtaki and colleagues isolated a 54-residue C-terminally amidated peptide from human placenta, encoded by the KiSS-1 gene, and named it metastin because of the gene’s earlier association with metastasis suppression in cell models [2]. Kotani and colleagues independently isolated 54-, 14- and 13-residue peptides sharing a common RF-amide C terminus and named them kisspeptins [1].

Kisspeptin-10 is the C-terminal decapeptide shared by these longer forms (sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2). In the receptor characterisation work, kisspeptins bound rat and human GPR54 expressed in Chinese hamster ovary cells with low nanomolar affinity, and receptor activation stimulated PIP2 hydrolysis, calcium mobilisation, arachidonic acid release, ERK1/2 and p38 MAP kinase phosphorylation and stress fibre formation [1]. This profile is typical of a Gq/11-coupled receptor, and it is the basis for using kisspeptin-10 as a defined agonist in in vitro assays of KISS1R signalling.

Kisspeptin as a probe of GnRH-neuron activation

The most widely cited animal-model work established that kisspeptin acts at the level of the GnRH neuron itself. In mice, GPR54 transcripts were found to colocalise with GnRH neurons; kisspeptin raised LH and FSH in wild-type animals but had no effect in mice lacking Gpr54; and in sheep, central kisspeptin produced a marked release of GnRH into cerebrospinal fluid, measured directly [3]. Together these observations positioned GPR54 as a key control point in the reproductive axis and kisspeptin as a direct GnRH-releasing signal in these models.

Electrophysiology in brain slices then showed what happens at the cellular level. Using GnRH-GFP mice, Han and colleagues reported that kisspeptin evoked a potent, long-lasting depolarisation of more than 90% of adult GnRH neurons, while a much smaller fraction of neurons responded in juvenile and prepubertal animals [4]. Around 90% of GnRH neurons expressed GPR54 mRNA at both ages, which led the authors to propose that the developmental change reflects both increased kisspeptin input and a post-transcriptional change in receptor signalling within the GnRH neuron [4].

In practice, this means researchers use kisspeptin-10 in three main ways:

• as a reference agonist in cell-based KISS1R assays (calcium imaging, IP accumulation, kinase phosphorylation);
• as a stimulus in slice electrophysiology to test whether identified GnRH neurons are responsive, and how that responsiveness changes with developmental stage or steroid environment;
• as a probe in animal models, where an LH response is used as a functional read-out of an intact kisspeptin-GnRH connection.

KNDy neurons: the upstream pulse generator

Much current work focuses on where endogenous kisspeptin comes from. In the arcuate nucleus, a population of neurons co-expresses kisspeptin, neurokinin B and dynorphin, giving them the name KNDy neurons. Navarro and colleagues showed by in situ hybridisation that arcuate Kiss1 neurons in female mice also express the genes for dynorphin and neurokinin B, as well as their receptors (the kappa opioid receptor and NK3), and that this expression is inhibited by estradiol [5]. They proposed a model in which neurokinin B and dynorphin act on the kisspeptin neurons themselves to synchronise and shape pulsatile kisspeptin output, which then drives GnRH release from fibres in the median eminence [5].

A widely cited review by Lehman, Coolen and Goodman describes KNDy cells as a central node in the control of GnRH secretion, drawing together anatomical and functional data from several species [6]. For researchers, the KNDy model explains why exogenous kisspeptin-10 is so useful: it lets an experiment bypass the upstream pulse generator and test the downstream GnRH neuron directly.

Oxytocin: an OXTR research ligand

Oxytocin is a nine-residue peptide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) with a disulfide bridge between the two cysteine residues that closes a six-residue ring, and an amidated C terminus. It belongs to the neurohypophysial peptide family together with vasopressin, from which it differs by two residues. That close structural relationship is important experimentally, because oxytocin and vasopressin receptors form a related family and cross-reactivity has to be considered when interpreting results [7].

Receptor structure and signalling

The oxytocin receptor is a typical class A GPCR that couples mainly through Gq proteins to PLC-beta [7]. Two allosteric factors stand out in the literature. First, the high-affinity receptor state depends on both magnesium ions and membrane cholesterol [7]. Second, these dependencies now have a structural explanation: the crystal structure of the human oxytocin receptor, solved in complex with a non-peptide antagonist, revealed a cholesterol molecule bound in an unexpected position between transmembrane helices IV and V and identified a conserved coordination site for Mg2+ that acts as a positive allosteric modulator of agonist binding [8].

For assay design, these findings have direct practical consequences. Membrane preparations or cell lines with altered cholesterol content, and buffers without divalent cations, can shift apparent oxytocin affinity. Studies indicate that controlling these variables is part of producing reproducible OXTR binding data [7, 8].

Beyond Gq, the receptor’s signalling repertoire is broader than a single pathway. A review by Busnelli and Chini summarises how OXTR couples to different G proteins, which signalling cascades it activates in neuronal and glial cells, and how receptor trafficking at the plasma membrane and inside the cell shapes the size and persistence of the response [9].

Receptor desensitisation and trafficking

Like many GPCRs, OXTR does not respond indefinitely to continued agonist exposure. After activation, receptors are phosphorylated, recruit arrestin proteins and are internalised, after which they can be recycled to the membrane or degraded. Reviews of the system describe how this regulation, together with steroid-dependent changes in receptor expression, controls how strongly a given tissue responds to oxytocin [7, 9]. In cell-based work this matters for experimental design: repeated or prolonged agonist exposure can reduce the measured response, so time-course controls and receptor-expression measurements are often reported alongside functional read-outs.

Hypothalamic magnocellular neurons

The main site of oxytocin gene expression is the population of magnocellular neurons in the paraventricular and supraoptic nuclei of the hypothalamus. These neurons project to the posterior pituitary, where oxytocin is released into the circulation, but they also release oxytocin within the hypothalamic nuclei themselves, and oxytocin neurons project widely through the central nervous system [7].

A notable feature of these cells is dendritic release. Ludwig and Leng described how neuropeptides such as oxytocin and vasopressin are released from dendrites, acting as autocrine or paracrine signals at their site of origin, and how activity-dependent priming of dendritic vesicle stores could reorganise local networks for extended periods [10]. This makes the magnocellular system a model of choice for studying how a single peptide can act both as a circulating hormone and as a local neuromodulator.

In vitro and animal-model research

Oxytocin is used as a reference agonist in a range of experimental settings:

• receptor binding and functional assays in cell lines expressing recombinant OXTR, including studies of allosteric modulation by Mg2+ and cholesterol;
• calcium imaging and second-messenger assays to characterise Gq-dependent signalling;
• trafficking studies following receptor internalisation and recycling;
• slice and in vivo electrophysiology of supraoptic and paraventricular neurons;
• tissue and organ-bath preparations in which receptor-expressing smooth muscle is used as a functional assay in animal tissue.

Reviews also describe oxytocin receptor expression in peripheral tissues such as kidney, heart, thymus, pancreas and adipocytes in animal studies, which gives researchers a range of tissues in which to compare receptor regulation [7].

Researchers can find the peptide on our oxytocin acetate product page.

Where the kisspeptin and oxytocin systems intersect

The two systems are often studied separately, but there are several points of overlap that make them useful to consider together.

Kisspeptin and supraoptic oxytocin neurons

The most direct link comes from electrophysiology. Scott and Brown recorded single supraoptic neurons in anaesthetised female rats and found that kisspeptin-10 acting in the periphery increased the firing rate of oxytocin neurons, whereas only a minority of vasopressin neurons responded, with short high-frequency bursts [11]. Kisspeptin-10 delivered centrally did not alter firing. When vagal afferents were desensitised, the peripheral effect on oxytocin neurons was prevented, suggesting that kisspeptin reached the supraoptic nucleus through vagal afferent input, acting as a hormone rather than as a local neuropeptide in this system [11].

This finding is a good example of why the site of action and circuit context matter when interpreting research-ligand data: the same peptide produced different results depending on whether it acted inside or outside the brain in this rat model.

Shared signalling logic

Both KISS1R and OXTR are Gq-coupled GPCRs on hypothalamic neurons, and both produce calcium-dependent changes in excitability [1, 7]. This shared biochemistry means many of the same assay platforms (calcium imaging, IP accumulation, kinase phosphorylation, patch-clamp recording) can be used for both, which simplifies comparative studies.

Steroid sensitivity

Both systems are strongly shaped by gonadal steroids. Arcuate Kiss1, dynorphin and neurokinin B expression is inhibited by estradiol in mice [5], and the regulation of the oxytocin system by gonadal and adrenal steroids is described as one of its most remarkable, and least understood, features [7]. Experiments that compare responsiveness across steroid conditions are therefore common in both fields, and controlling the endocrine state of animal models is a standard design consideration.

Peptide release from hypothalamic neurons

Finally, both systems rely on neurosecretory release from hypothalamic neurons: kisspeptin from KNDy and other kisspeptin populations onto GnRH neurons and their terminals [5, 6], and oxytocin from magnocellular neurons both to the pituitary and locally through dendrites [7, 10]. Studies that ask how peptide release is coordinated across neuron populations draw on both literatures.

Laboratory considerations for lyophilised peptides

The points below describe general laboratory practice for short synthetic peptides of this type. They are not specific instructions, and each laboratory should follow its own standard operating procedures and safety rules.

Storage

Lyophilised (freeze-dried) peptides are generally stored at -20°C, protected from light and moisture, in a sealed container with desiccant where possible. Before opening, letting the vial reach room temperature reduces condensation on the dry powder. Our peptide storage guide covers temperature, light and humidity in more detail, and our article on peptide lyophilisation explains why the freeze-dried state is the most stable form for storage.

Reconstitution as laboratory chemistry

Reconstitution means dissolving the lyophilised solid in a suitable solvent to make a stock solution of known concentration for in vitro or analytical work. The variables are the solvent, the volume and the resulting concentration:

• Solvent. Many short peptides dissolve in sterile, high-purity water. Oxytocin is generally water-soluble. Kisspeptin-10 contains several aromatic and hydrophobic residues, so some laboratories use a small proportion of a compatible co-solvent, or a dilute aqueous acid, before diluting into an assay buffer. The solvent should be compatible with the downstream assay.
• Volume and concentration. Stock concentration is the mass of peptide divided by the volume of solvent added. Laboratories usually record the calculation on the tube label and in the lab notebook, and correct for net peptide content if that information is available.
• Technique. Gentle swirling rather than vigorous shaking limits foaming and surface adsorption. Low-binding tubes can reduce peptide loss for dilute solutions.

Handling and stability in solution

Peptides in solution are less stable than the dry powder. Common practice is to divide a stock into single-use aliquots, store them frozen, and avoid repeated freezing and thawing. Oxytocin’s disulfide bond and kisspeptin-10’s tryptophan residue can both be sensitive to oxidation, so limiting air exposure and light is reasonable. Working dilutions are typically prepared fresh on the day of the experiment.

Analytical identity confirmation

As a general laboratory practice, many research groups confirm the identity and integrity of a peptide before starting a study, for example by chromatographic purity assessment and mass-based identity confirmation in their own facility or a contract laboratory. This is part of good experimental hygiene and helps rule out degradation as a cause of unexpected results. Product pages show a class-level specification where one is on record. For kisspeptin-10, reports for selected lots independently tested are searchable by batch or report code at certapeptides.com/verify.

Kisspeptin-10 is available on our kisspeptin-10 product page, and both peptides are listed in the gonadotropic research category.

Key takeaways

• The gonadotropic pathway, or HPG axis, is studied mainly as a neurobiological question: how hypothalamic neurons generate and regulate GnRH output, measured through pituitary hormone read-outs in models.
• Kisspeptin-10 is the C-terminal decapeptide of the kisspeptins, the endogenous ligands of KISS1R/GPR54, a Gq/11-coupled receptor [1, 2].
• Animal-model and slice studies indicate that kisspeptin acts directly on GnRH neurons through GPR54 [3, 4], which makes kisspeptin-10 a standard probe of GnRH-neuron activation.
• Arcuate KNDy neurons are thought to act as the upstream pulse generator that supplies endogenous kisspeptin [5, 6].
• Oxytocin is a cyclic nonapeptide that acts on OXTR, a Gq-coupled GPCR whose high-affinity state depends on Mg2+ and cholesterol [7, 8]; receptor trafficking and desensitisation shape response size and duration [9].
• Magnocellular oxytocin neurons release peptide both to the pituitary and locally from dendrites [7, 10].
• The systems intersect: in a rat model, kisspeptin-10 acting peripherally increased supraoptic oxytocin-neuron firing through vagal afferents [11].
• Lyophilised peptides are generally stored at -20°C; reconstitution is a matter of solvent, volume and concentration; aliquoting and identity confirmation are good general practice.

Frequently asked questions

What does “gonadotropic research” cover?

It covers laboratory research on the hypothalamic-pituitary-gonadal axis, particularly the hypothalamic neurons and receptors that control GnRH and pituitary hormone release. Typical work includes receptor pharmacology in cell lines, slice electrophysiology and animal-model studies in which hormone levels are used as read-outs.

Which receptor does kisspeptin-10 act on?

Kisspeptin-10 is an agonist of KISS1R, originally described as the orphan receptor GPR54. In cell-based studies, receptor activation stimulated PIP2 hydrolysis, calcium mobilisation and MAP kinase phosphorylation, consistent with Gq/11 coupling [1].

How does kisspeptin-10 differ from longer kisspeptins?

The longer endogenous forms (54, 14 and 13 residues) share the same RF-amide C-terminal sequence [1, 2]. Kisspeptin-10 is that shared C-terminal decapeptide, which makes it a convenient, short synthetic agonist for receptor studies.

What are KNDy neurons?

KNDy neurons are arcuate nucleus neurons that co-express kisspeptin, neurokinin B and dynorphin. Research suggests they generate the pulsatile kisspeptin signal that drives GnRH release in rodent and other animal models [5, 6]. Our kisspeptin-10 article discusses them further.

How does the oxytocin receptor signal?

OXTR is a class A GPCR that couples mainly through Gq proteins to phospholipase C-beta, raising intracellular calcium [7]. Its high-affinity state depends on Mg2+ and cholesterol, both of which are explained by the receptor’s crystal structure [8]. It can also engage other signalling pathways and is regulated by internalisation and recycling [9].

Is there evidence that kisspeptin affects oxytocin neurons?

In anaesthetised female rats, kisspeptin-10 acting peripherally increased the firing of supraoptic oxytocin neurons, an effect prevented by desensitising vagal afferents; central kisspeptin-10 did not alter firing in that study [11].

How should lyophilised peptides be stored in the lab?

As a general rule, at -20°C, dry, protected from light and in a sealed container. Once reconstituted, solutions are usually aliquoted and frozen to avoid repeated freezing and thawing. See our storage guide for details.

References

1. Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001;276(37):34631-34636. doi:10.1074/jbc.M104847200
2. Ohtaki T, Shintani Y, Honda S, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411(6837):613-617. doi:10.1038/35079135
3. Messager S, Chatzidaki EE, Ma D, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci U S A. 2005;102(5):1761-1766. doi:10.1073/pnas.0409330102
4. Han SK, Gottsch ML, Lee KJ, et al. Activation of gonadotropin-releasing hormone neurons by kisspeptin as a neuroendocrine switch for the onset of puberty. J Neurosci. 2005;25(49):11349-11356. doi:10.1523/JNEUROSCI.3328-05.2005
5. Navarro VM, Gottsch ML, Chavkin C, et al. Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the mouse. J Neurosci. 2009;29(38):11859-11866. doi:10.1523/JNEUROSCI.1569-09.2009
6. Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology. 2010;151(8):3479-3489. doi:10.1210/en.2010-0022
7. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629-683. doi:10.1152/physrev.2001.81.2.629
8. Waltenspühl Y, Schöppe J, Ehrenmann J, Kummer L, Plückthun A. Crystal structure of the human oxytocin receptor. Sci Adv. 2020;6(29):eabb5419. doi:10.1126/sciadv.abb5419
9. Busnelli M, Chini B. Molecular basis of oxytocin receptor signalling in the brain: what we know and what we need to know. Curr Top Behav Neurosci. 2018;35:3-29. doi:10.1007/7854_2017_6
10. Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci. 2006;7(2):126-136. doi:10.1038/nrn1845
11. Scott V, Brown CH. Kisspeptin activation of supraoptic nucleus neurons in vivo. Endocrinology. 2011;152(10):3862-3870. doi:10.1210/en.2011-1181

Disclaimer

For research purposes only. This article is educational; the compounds discussed are sold for laboratory research and are not for human consumption.

For research purposes only. Nothing here is legal advice — import rules are set by national authorities and change; when in doubt, consult your country’s regulator.

The email we keep receiving

A researcher orders peptides from a supplier in the UK or the US. The parcel enters the EU, hits a customs inspection, and is classified not as a research chemical but as an unauthorised medicinal product. The shipment is seized or returned, the money is gone, and the research timeline with it. This week an Estonian customer told us exactly that story about a previous UK order — and he is far from the first.

The frustrating part: in most of these cases nobody did anything “wrong”. The products were labelled for research use, the paperwork was filled in correctly, and the parcel was still held. To understand why, you need to look at where the customs border actually sits.

Why third-country parcels get seized

Every parcel that enters the EU from outside it — and since Brexit, that includes every parcel from the UK — goes through customs clearance. At that point three things work against research compounds:

• Member-state classification. Several EU countries treat certain peptides as medicinal products under national law. When a parcel from a third country is inspected, the import is assessed against that national classification — and an unauthorised medicine cannot be imported by a private buyer, whatever the label says.
• Inspection is discretionary. Most parcels pass; some are opened. A seizure is not a statement about the supplier’s quality or your intent — it is a lottery you enter every time a parcel crosses a customs border.
• No practical recourse. Contesting a customs seizure of a research compound is slow, usually requires proving authorisation you do not have as a private researcher, and almost never succeeds. Most buyers simply absorb the loss.

The intra-EU difference

Inside the European Union, goods move under the principle of free movement. A parcel sent from Romania to Estonia, Germany, or Spain crosses no customs border, files no import declaration, and passes no import inspection. There is no clearance step at which the parcel could be reclassified, held, or seized on import — because there is no import. It is, administratively, the same as a domestic shipment.

This is not a loophole; it is the design of the single market. The customs exposure that costs researchers their UK and US orders simply does not exist for an EU-internal shipment.

The practical consequences for an EU-based lab:

• No customs clearance — and therefore no clearance delays, which routinely add one to three weeks to third-country orders even when nothing is seized.
• No import VAT or handling fees collected at the door.
• Predictable transit — the parcel moves carrier-to-carrier, trackable end to end, with no black-box “held by customs” phase.

What to check before you order

If customs exposure matters to you, three questions separate suppliers:

1. Where does the parcel physically ship from? Not where the company is registered — where the warehouse is. A UK company shipping from a UK warehouse puts an EU customer through customs; an EU warehouse does not. We ship every order from Romania. (Our non-EU destinations — the UK and Switzerland — do clear customs on arrival, and we say so at checkout rather than letting it surprise anyone.)
2. Is the tracking transparent end to end? A supplier confident in its logistics shows you every scan, including carrier handoffs. Ours is at certapeptides.com/track.
3. Does the supplier publish independent testing? Customs risk is only one failure mode; quality is the other. Our approach to third-party verification is covered in how to verify a peptide supplier’s legitimacy and the 2026 EU supplier guide.

The bottom line

If your laboratory is in the EU, the cheapest customs strategy is not better paperwork — it is ordering from inside the single market, so there is no customs event at all. That single decision removes the seizure risk, the import fees, and the clearance delay in one move.

Questions about shipping to your country are answered on our FAQ and shipping page, or ask us directly — a human reads every message at support@certapeptides.com.

All CertaPeptides products are supplied strictly for laboratory and research purposes only. Not for human consumption, diagnosis, or treatment.

A peptide Certificate of Analysis (COA) is a test report on a sample from one specific lot. Depending on the tests the lab ran, it reports an identity result (typically whether the measured mass matches the molecule on the label), purity (the main peak’s share of the total detected peak area) or content. The strongest form is a COA you can independently verify against the issuing third-party lab, rather than an in-house document you have to take on trust. You read it by checking, in order, the compound name and any lot identifier the report gives, the results of the tests it covers and the issuing lab. You then look the report up on the public page of the testing lab or its certificate provider, using the identifiers printed on the report (for Janoshik, the task number and the unique key), and compare the two. Everything below walks through each field, then shows how to verify a real Janoshik report so you are reading the lab’s copy, not a PDF that could have been edited.

For research purposes only. The information here describes how to interpret analytical identity and purity data on a laboratory document. It is not guidance on safety for use, human consumption, or any application beyond laboratory research. CertaPeptides is a reseller of research compounds, not a manufacturer or testing laboratory.

What a peptide Certificate of Analysis actually tells you

A COA answers only the analytical questions its tests cover, for a sample from one specific batch. The two most common are:

• Identity — is the substance in the vial the peptide named on the label? This is established primarily by mass spectrometry (MS), which measures the molecule’s mass so it can be matched against the expected molecular weight of the named peptide.
• Purity — of the components the instrument detects, what share is the target peptide rather than synthesis by-products or truncated sequences? This is established primarily by high-performance liquid chromatography (HPLC), which separates a sample’s components and reports the main peak as a percentage of the total detected peak area. Note that HPLC area-percent is not a total mass fraction: it does not account for salts, water, or counterions, and it does not see non-UV-absorbing impurities. Residual solvents and reagents need separate methods.

A COA is batch-specific. It applies to the lot it was generated from, not to the product line in general. That is why the lot/batch number on the report is as important as the purity figure: a COA with no lot number, or with a lot number that does not match the vial you hold, does not establish results for that vial.

How to read each field of a peptide COA

Real reports vary in layout and in the tests they cover, but a credible third-party peptide COA usually contains these core fields. Here is what each one means and what a careful reader checks.

1. Compound name and stated quantity

The top of the report usually names the peptide tested and the nominal amount (for example, a 10 mg lyophilised sample). Check that this matches the product you are verifying. Note that a peptide can be supplied as different salt forms; the named compound on a COA reflects what was submitted to the lab. As a reseller, we list the material as our supplier provides it.

2. Lot / batch number

The single most important traceability field. The lot number ties the report to a physical batch. To trust a COA, the lot on the report must correspond to the batch you received. A report whose lot number is blank, generic, or unrelated to your shipment does not establish results for the vial in front of you.

3. HPLC purity (the headline number)

HPLC separates everything in the sample over time and produces a chromatogram — a trace with peaks. The target peptide elutes as one peak; impurities appear as additional, usually smaller, peaks. The reported purity is the area of the main peak expressed as a percentage of the total peak area. When a COA says, for instance, that a peptide is above 98% pure by HPLC, it means the main peak accounts for that share of the total detected peak area. Read the chromatogram itself, not just the headline number: a clean trace shows one dominant, well-resolved peak; a noisy trace with several large secondary peaks deserves scrutiny even if the stated percentage looks high.

4. Mass spectrometry (identity confirmation)

HPLC tells you how pure the main component is; it does not, on its own, prove that component is the right molecule. That is what mass spectrometry is for. The MS section reports the measured mass of the dominant species. A genuine identity confirmation shows the observed mass matching the theoretical molecular weight of the named peptide (within the instrument’s expected tolerance). If a report shows a high HPLC purity but the MS mass does not correspond to the named compound, the material may be pure — but pure something else.

5. Additional panels (when present)

Some reports include other independent tests, such as an endotoxin (LAL) assay or a heavy-metals panel, beside or instead of identity and purity results. These are separate analyses, reported in their own section or in a report of their own. Their presence or absence does not change how you read any identity and purity results the report gives — it tells you which tests the report covers.

6. Issuing laboratory and report ID

A third-party COA names the independent lab that performed the testing and usually carries a report identifier or verification code. This is what makes the document checkable. The lab name and the report’s identifiers are what you use to look the report up and compare it with the issuer’s own record, which is the next step.

How to verify a Janoshik report (step by step)

We publish independent third-party Janoshik Analytical reports for tested batches — Janoshik is an independent analytical laboratory in the Czech Republic that runs a verification portal for its reports. Not every lot carries a published report, so check the COA / Verify badge on the specific product you are looking at. Verification matters because a PDF can be altered — numbers changed, a lab’s name pasted onto someone else’s data. Looking the report up on the lab’s own system lets you read the lab’s copy, generated by the lab, instead of a file forwarded to you, and compare the two.

1. Find the task number and unique key. Both are printed on the Janoshik reports we publish. Our own batch verification tool also finds a published report by its report code, and by the lot code on your vial where the report records that lot, and links to its record.
2. Open the lab’s verification portal in a browser. Go to janoshik.com/verification in a normal web browser (Chrome, Safari, or Firefox).
3. Enter both and compare. The lab’s own record loads with the identifying details and measured results that report contains. Compare every field against the COA you were given. They should match exactly. Any discrepancy — a different purity figure, a different lot, a missing section — means the document you hold does not match the lab’s current record: treat it as unverified until the issuer explains the difference.

To make this concrete, one of our published reports carries the Janoshik verification code P29STAYN1SF6 (the unique key). You can look that code up in our verification tool, which links straight through to the lab’s record, and check for yourself that the report we show matches the lab’s record. On the lab’s own verification page, enter 233644 as the task number and P29STAYN1SF6 as the unique key. The report’s Sample field reads KPV 10mg and its Batch field reads CP-2607-KPV10, and the vial in the photo attached to the report carries the same lot code, so it is a report on a sample from a vial labelled with that lot code, not on the compound in general. Its Results table has two filled rows: KPV 11.93 mg, the content measured in the tested vial, and Purity 98.786%. The record names no test method, attaches no chromatogram and gives no mass-spectrometry result, so it answers only what those two rows state. The analysis is dated 18 September 2026. That is the whole point of independent verification: you should not have to take our word for it.

How to spot a fake or edited COA

Most fraudulent or misleading COAs fail one of a small number of checks. Run through this list before trusting any peptide certificate of analysis:

• No issuing lab named, or a lab that cannot be looked up. A real third-party COA names the lab and usually carries a report ID you can check with that lab. If there is no lab, no report number, or no way to check it on a public page of the lab or its certificate provider, treat it as unverified.
• The report cannot be found on the public page of the lab or its certificate provider. Check that you entered every identifier the page asks for exactly as printed (for Janoshik, the task number and the unique key); until the report is found, treat the document as unverified. If it loads a record that disagrees with the PDF, the PDF does not match the current public record: treat it as unverified until the issuer resolves the discrepancy. The lookup compares the document with the issuer’s current record; whether the report belongs to your vial is a separate check (the lot number).
• Missing lot number, or a lot that does not match your batch. A COA with no traceable lot does not establish results for the vial in front of you.
• Purity claimed with no chromatogram. A bare “99% pure” statement with no HPLC trace gives you nothing to inspect. Where a report gives an HPLC purity figure, ask to see the chromatogram behind it, so you can check the peak resolution.
• HPLC percentage but no mass-spec identity. Purity without identity confirmation answers only one of the two questions: HPLC gives the main peak’s share of the detected peak area, and whether that peak is the right molecule needs its own assessment.
• Figures that look retyped onto an image. Mismatched fonts, a purity number in a different typeface from the rest of the page, or a value that contradicts the chromatogram are signs of editing. When in doubt, ignore the PDF and look the report up yourself on the public page of the lab or its certificate provider.
• A single COA reused across many batches. Because a COA is batch-specific, the same report attached to unrelated lots is a red flag — each batch should have its own.

What HPLC purity is considered good for research peptides?

For research-grade peptides, an HPLC purity at or above roughly 98% is a common benchmark for a well-made synthetic peptide, and many credible reports sit in the 98–99%+ range. But the percentage is only meaningful alongside the rest of the report: a high number on a noisy chromatogram, or with no mass-spec identity confirmation, or on a lot you cannot trace, is weaker evidence than a slightly lower number on a clean, fully verifiable report. Purity describes analytical composition for laboratory characterisation; it is not a statement about suitability for any use. Always weigh the purity figure together with any identity result the report provides, the quality of any chromatogram it includes, and whether the report can be looked up on a public page of the issuing lab or its certificate provider.

The COA and the verification tool: how they work together

This guide is the educational companion to our live tooling. Use them together:

• Read this page to understand what each field on a COA means and how to check a report against the lab’s own record.
• Enter the code printed on your vial label, or a lab report code, in the batch verification tool. It shows what CertaPeptides publishes for that code and, for a withdrawn lot, the withdrawal and its reason. If the code finds nothing, email us that code.
• For the background on why we test in the first place and what the results have shown, read why we send our products to Janoshik and what they found.

Frequently asked questions

What is a peptide COA?

A peptide Certificate of Analysis is a laboratory report on a tested sample from one specific batch, issued by the manufacturer, by the seller’s own lab or by an independent lab. Depending on the tests run, it reports whether the measured mass matches the peptide named on the label (typically by mass spectrometry), gives the main peak’s share of the total detected peak area (HPLC purity) or states the peptide content of the vial it tested (content), which is only an estimate for other vials of the batch. It names its issuer; an independent lab’s report usually also carries a report ID that you can check with that lab.

How do I verify a Janoshik report?

Take the task number and unique key printed on the COA, open janoshik.com/verification in a normal web browser, and enter both. The lab’s own record loads with the identifying details and measured results that report contains; compare each field against the COA you were given. The portal is built for human browsers and may block command-line/automated requests, so use a browser. Our verification tool finds a published report by its report code, and by the lot code on your vial where the report records that lot; it links to the report’s record on a public certificate page hosted by the testing lab or its certificate provider.

What purity is good for research peptides?

An HPLC purity at or above about 98% is a common benchmark for well-made synthetic research peptides, with many credible reports in the 98–99%+ range. The figure should always be read together with any mass-spec identity result the report provides, the quality of any chromatogram it includes, and whether the report can be looked up on a public page of the issuing lab or its certificate provider — a verifiable, clean report matters more than a higher number you cannot check. Purity is an analytical measure for laboratory characterisation, not a statement about safety or suitability for use.

Does a high HPLC percentage alone prove the peptide is correct?

No. HPLC purity gives the dominant peak’s share of the total detected peak area; it does not prove that component is the intended molecule. Mass spectrometry provides that identity confirmation by matching the measured mass to the named peptide’s molecular weight. Each test answers its own question, so check which of them a report covers.

Sources

• Janoshik Analytical — independent third-party analytical laboratory (Czech Republic) providing HPLC and mass-spectrometry testing and a public report-verification portal: janoshik.com · verification page: janoshik.com/verification
• CertaPeptides batch verification tool (Janoshik reports for the tested lots we publish): certapeptides.com/verify

Last reviewed: June 2026.

{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “What is a peptide COA?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “A peptide Certificate of Analysis is a laboratory report on a tested sample from one specific batch, issued by the manufacturer, by the seller’s own lab or by an independent lab. Depending on the tests run, it reports whether the measured mass matches the peptide named on the label (typically by mass spectrometry), gives the main peak’s share of the total detected peak area (HPLC purity) or states the peptide content of the vial it tested (content), which is only an estimate for other vials of the batch. It names its issuer; an independent lab’s report usually also carries a report ID that you can check with that lab.”
}
},
{
“@type”: “Question”,
“name”: “How do I verify a Janoshik report?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Take the task number and unique key printed on the COA, open janoshik.com/verification in a normal web browser, and enter both. The lab’s own record loads with the identifying details and measured results that report contains; compare each field against the COA you were given. The portal is built for human browsers and may block command-line or automated requests, so use a browser. CertaPeptides’ verification tool finds a published report by its report code, and by the lot code on the vial where the report records that lot; it links to the report’s record on a public certificate page hosted by the testing lab or its certificate provider.”
}
},
{
“@type”: “Question”,
“name”: “What purity is good for research peptides?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “An HPLC purity at or above about 98% is a common benchmark for well-made synthetic research peptides, with many credible reports in the 98 to 99%-plus range. The figure should always be read together with any mass-spectrometry identity result the report provides, the quality of any chromatogram it includes, and whether the report can be looked up on a public page of the issuing lab or its certificate provider. Purity is an analytical measure for laboratory characterisation, not a statement about safety or suitability for use.”
}
},
{
“@type”: “Question”,
“name”: “Does a high HPLC percentage alone prove the peptide is correct?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No. HPLC purity gives the dominant peak’s share of the total detected peak area; it does not prove that component is the intended molecule. Mass spectrometry provides that identity confirmation by matching the measured mass to the named peptide’s molecular weight. Each test answers its own question, so check which of them a report covers.”
}
}
]
}

For research purposes only. Not for human consumption. Consult applicable regulations in your jurisdiction. CertaPeptides (CERTALAB S.R.L.) is a reseller of research compounds and is not the testing laboratory; independent analysis referenced here is performed by Janoshik Analytical.

For laboratory research purposes only. Not for human consumption.

Belgian researchers sourcing peptide compounds for in-vitro and preclinical studies are working in a market that shifted noticeably over the past year. Peptide Sciences, one of the most-cited US benchmark suppliers, voluntarily discontinued all operations on 6 March 2026. That closure removed a common reference point for the research community and pushed demand toward EU-based alternatives that ship without customs delays. This guide covers what actually matters in that sourcing decision for Belgium: the legal framework, COA standards, logistics, and the criteria that separate genuine research-grade suppliers from the rest.

---

Is It Legal to Buy Research Peptides in Belgium?

Synthetic peptides sold as research chemicals sit at the intersection of two Belgian regulatory frameworks, and knowing which one applies is what makes sourcing compliant. Because Belgium is officially trilingual (Dutch, French, German), its institutions and statutes carry parallel names, and this guide gives both the Dutch and French forms where relevant.

The medicines framework (Law of 25 March 1964). Belgium’s principal medicines statute, the Law of 25 March 1964 on medicines, sets the framework for medicinal products for human use, transposing the EU rules of Directive 2001/83/EC. Broadly, a substance is treated as a medicinal product when it is presented as having properties for treating or preventing disease, or when it is administered to restore, correct, or modify physiological functions. A peptide sold exclusively for in-vitro research, labelled “not for human consumption” and carrying no therapeutic claims, generally falls outside that definition. Classification turns on presentation, composition, and intended use, so the label alone is not an automatic exemption. Medicines advertising in Belgium is regulated by the Royal Decree of 7 April 1995 and enforced by the Federal Agency for Medicines and Health Products: in Dutch the Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG), in French the Agence fédérale des médicaments et des produits de santé (AFMPS), commonly cited in English by the acronym FAMHP. The agency was established on 1 January 2007 and is the licensing and pharmacovigilance authority for medicines in Belgium.

The controlled-substances framework (Law of 24 February 1921 + Royal Decree of 6 September 2017). Belgium’s narcotics and psychotropics regime rests on the Law of 24 February 1921 on the trade in poisonous, soporific, narcotic, psychotropic, disinfectant and antiseptic substances, with the detailed lists set out in the Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. The FAMHP administers this regime through its dedicated narcotics function. Standard research peptides such as BPC-157, TB-500, GHK-Cu, Epitalon, Selank, Ipamorelin, and most growth hormone secretagogues are not the scheduled narcotic or psychotropic substances this framework targets. Working with scheduled substances for scientific purposes requires specific administrative authorisation from the FAMHP, but that regime does not reach unscheduled research peptides.

Two areas carry elevated risk:

GLP-1 class compounds. Semaglutide, tirzepatide, and liraglutide are authorised medicinal substances in Belgium and carry elevated regulatory and import scrutiny. Any framing that presents them as therapeutic alternatives to prescription medicines brings them within the medicines framework and its advertising rules, which the FAMHP actively enforces. Framing must stay strictly scientific, and researchers should confirm import and handling requirements through their own institution.

Novel compounds. The schedules under the Royal Decree of 6 September 2017 are subject to update, and newer psychoactive compounds can be added; a 2017 reform was specifically designed to make it easier to bring synthetic substances under control. Researchers should verify the current status of any novel compound before ordering.

In practice: Belgian customs is the General Administration of Customs and Excise (in Dutch the Algemene Administratie van de Douane en Accijnzen, in French the Administration générale des douanes et accises), part of the Federal Public Service Finance. It generally treats shipments moving within the EU as internal-market movements rather than dutiable imports. Such intra-EU movements are generally not subject to import duties or routine inspection, though restricted, mislabelled, or unlawful goods can still be stopped. Orders arriving from outside the EU may be examined and held.

---

Why EU-Domestic Shipping Matters for Belgian Researchers

Belgium is a founding EU member and sits inside the EU customs union, where customs duties between member states are prohibited and goods that have entered free circulation move without internal tariffs or routine border checks (TFEU Articles 28-30). Suppliers with EU-based warehouses ship peptide orders without the customs delay, documentation burden, or seizure risk that affect shipments arriving from outside the EU. Typical delivery windows from EU warehouses to Belgium:

• Western/Central EU (Romania, Slovakia, Czech Republic): 2–4 business days
• Northern EU (Baltic states): 3–5 business days
• UK-based suppliers: subject to EU import controls post-Brexit; 5–10+ days with variable customs outcomes

For time-sensitive research protocols or compounds that benefit from a short transit, EU-domestic shipping is strongly preferred. Belgium’s central position and dense logistics network (the ports of Antwerp and Zeebrugge, plus Brussels and Liège air hubs) means intra-EU parcels typically clear quickly.

---

How to Evaluate a Research Peptide Supplier: The COA Standard

A Certificate of Analysis (COA) is the central quality document in research peptide procurement. Its evidentiary value depends entirely on who produced it and how.

The minimum acceptable COA

An acceptable third-party COA for research-grade peptides must include:

• HPLC purity (%): High-Performance Liquid Chromatography with the chromatogram included. Purity should be 98% or higher for research-grade material; 99%+ is achievable and increasingly common among quality suppliers.
• Identity confirmation via LC-MS (Liquid Chromatography-Mass Spectrometry): the observed molecular mass must match the theoretical mass of the named peptide within standard instrument tolerance.
• Lot/batch number matching exactly what is printed on the vial. A COA from a different batch is not a COA for what was received.
• Testing laboratory name, address, and date. Independent labs issue reports on letterhead with contact information. Requests to “contact us for the COA” without a document are a red flag.
• No ownership link to the supply chain. The lab must not be owned by, operated by, or co-located with the manufacturer or vendor.

Janoshik Analytical: the EU research peptide reference lab

Janoshik Analytical (Czech Republic) has become the most widely used third-party testing laboratory for research peptides in the European market. Each of their reports shows the results measured on the sample it tested. Each Janoshik report we publish carries a task number that can be referenced in procurement documentation.

Extended COA parameters

Some EU suppliers now provide expanded COA packages: endotoxin testing (LAL assay), bioburden (microbial limit testing), heavy-metal screening (ICP-MS), and residual-solvent testing. These parameters matter for cell-culture and small-animal research where contamination artefacts could confound results. If your protocol is sensitivity-limited, request these extended parameters before ordering.

---

Sourcing Criteria Checklist for Belgian Research Institutions

For researchers at Belgian universities (KU Leuven, Ghent University, UCLouvain, ULB, University of Antwerp, VUB, University of Liège), research institutes such as VIB or Sciensano, or pharmaceutical companies ordering peptides for non-clinical studies, a standardised supplier-evaluation process reduces both quality risk and administrative overhead:

• COA on product page: independent third-party, correct lot number, HPLC + LC-MS minimum
• EU warehouse: confirmed EU-domestic shipping origin
• Delivery timeline documented: a stated SLA for Belgium specifically, not a generic “EU” figure
• Packaging standard: lyophilised vials in sealed glass, shipped with temperature-appropriate packaging
• Reconstitution documentation, covering bacteriostatic water compatibility, storage temperature (typically −20°C long-term), and solubility notes (aqueous vs organic solvent)
• Legal compliance statement: “for research purposes only, not for human consumption” on product page and packaging
• Invoice/documentation: commercial invoice for institutional procurement records, VAT-compliant billing

---

What Belgian Researchers Are Ordering in 2026

Research peptide classes commonly available to and studied by researchers sourcing from Belgium in 2026 include:

Healing and tissue-biology research: BPC-157.

Metabolic and receptor-biology research: GLP-1 class compounds (semaglutide, tirzepatide, retatrutide) for receptor pharmacology, islet-cell biology, and adipocyte studies. Note: these require strict research-only framing in all procurement and lab documentation.

Longevity and telomere-biology research: Epitalon (tetrapeptide), GHK-Cu (copper peptide), MOTS-c (mitochondrial-derived peptide). Interest in this cluster has grown following several high-profile publications.

Nootropic and CNS research: Selank, Semax, Dihexa. Academic interest in these neuropeptides has grown as source data from Eastern European research institutions becomes more accessible.

---

Storage and Handling for Research-Grade Peptides

Proper storage preserves peptide integrity and analytical validity. Standard protocols for lyophilised (freeze-dried) research peptides:

• Long-term storage: −20°C in the original sealed vial, protected from moisture and light
• Working aliquot (post-reconstitution): 4°C refrigerated, typically stable 2–4 weeks depending on the peptide
• Reconstitution vehicle: bacteriostatic water is standard for most peptides; 0.1% acetic acid is used for GH-releasing peptides (GHRP class) with poor aqueous solubility. Low-concentration dimethyl sulfoxide (DMSO) is used for select hydrophobic peptides, so confirm with the supplier’s reconstitution guide.
• Cycle count: minimise freeze-thaw cycles. Single-use aliquots are recommended for sensitive assays.

All storage notes above describe laboratory handling protocols for research compounds. They do not constitute instructions for human use.

---

Key Questions to Ask Any Supplier Before Ordering

1. Which independent laboratory performed the COA, and what was the lot number tested?
2. Can you provide the full COA document, rather than only the purity figure, before I place an order?
3. Where is your EU warehouse located, and what is the expected delivery time to [Belgian city or postal code]?
4. Do you ship with cold-chain packaging for GLP-1 class peptides?
5. What is your re-test policy if a received vial shows evidence of degradation?
6. Is your packaging labelled for research purposes only, with no human-use language?

---

Summary

Belgian researchers have access to a well-developed EU market for research-grade peptides. The legal picture is defined by two frameworks: the medicines regime under the Law of 25 March 1964 (administered by the FAMHP / FAGG / AFMPS) and the controlled-substances regime under the Law of 24 February 1921 and the Royal Decree of 6 September 2017. In practice the differentiators are COA quality (independent third-party, lot-matched, HPLC+MS minimum), EU-domestic shipping logistics, and strict research-only framing. Suppliers with transparent, publicly posted COAs and EU-based inventory are the appropriate starting point for institutional and academic procurement decisions.

CertaPeptides ships from within the EU to Belgium, posts Janoshik reports for selected lots on the product pages, and labels all compounds for research purposes only. No human-use claims are made.

---

This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.

Regulatory & Legal Sources

Primary, authoritative references for the regulatory framework outlined above. These are official national and EU bodies; verify the current status of any specific compound directly with them before ordering. For research purposes only.

• FAGG / AFMPS — Federal Agency for Medicines and Health Products.
• FOD Financiën — Douane (Belgian customs / FPS Finance).
• EUR-Lex — EU legal database (medicinal products and chemicals framework).
• European Medicines Agency (EMA) — EU-level authorisation and oversight of medicinal substances.

For laboratory research purposes only. Not for human consumption.

Italian researchers sourcing peptide compounds for in-vitro and preclinical studies are working in a market that shifted noticeably over the past year. The March 2026 closure of Peptide Sciences, one of the most-cited US benchmark suppliers, removed a common reference point for the research community and moved demand toward EU-based alternatives that ship without customs delays. This guide covers what actually matters in that sourcing decision for Italy: the legal framework, COA standards, logistics, and the criteria that separate genuine research-grade suppliers from the rest.

---

Is It Legal to Buy Research Peptides in Italy?

Synthetic peptides sold as research chemicals sit at the intersection of two Italian regulatory frameworks, and knowing which one applies is what makes sourcing compliant.

The Codice del farmaco (Medicines Code). Italy’s principal medicines law is the Decreto Legislativo 24 aprile 2006, n. 219, which implements EU Directive 2001/83/EC on medicinal products for human use. Under this framework, no medicinal product may be placed on the Italian market without a marketing authorisation (Autorizzazione all’Immissione in Commercio, or AIC) granted by the Agenzia Italiana del Farmaco (AIFA) or through an EU authorisation. A medicinal product is defined broadly: by its presentation as suitable for treating or preventing disease, or by being administered to restore, correct, or modify a physiological function. A peptide sold exclusively for in-vitro research, labelled “not for human consumption” and carrying no therapeutic claims, generally falls outside that definition. Classification turns on presentation, composition, and intended use, so the label alone is not an automatic exemption. AIFA is the public agency responsible for human medicines in Italy and operates under the supervision of the Ministry of Health.

The Testo Unico stupefacenti (Consolidated Narcotics Act). Italy’s controlled-substances framework is the Decreto del Presidente della Repubblica 9 ottobre 1990, n. 309, which lists narcotic and psychotropic substances in a set of ministerial tables (Tabella I and others). Standard research peptides such as BPC-157, TB-500, GHK-Cu, Epitalon, Selank, Ipamorelin, and most growth hormone secretagogues are not listed in these tables as of mid-2026. Substances in Table I are subject to the most rigorous control measures, and use of listed substances for scientific purposes requires specific administrative authorisation; that regime does not reach unlisted research peptides.

Research chemicals outside both frameworks. A peptide that is neither an authorised medicinal product nor a listed controlled substance, sold as research material with “not for human consumption” labelling, generally sits outside the AIC requirement and outside the narcotics tables. Depending on the substance, EU chemical-safety rules (CLP classification and labelling, and REACH) may also apply to its handling and supply. This is the category most quality research peptides occupy.

Two areas carry elevated risk:

GLP-1 class compounds. Semaglutide, tirzepatide, and liraglutide are active substances in separately authorised medicinal products in Italy and the wider EU, and they carry elevated regulatory and import scrutiny. Any framing that presents them as therapeutic alternatives to authorised medicines brings them under the Codice del farmaco and EU medicines-advertising rules. Framing must stay strictly scientific, and researchers should confirm import and handling requirements through their own institution.

Novel compounds. Italy’s narcotics tables are updated regularly. The Ministry of Health adds new psychoactive substances on the recommendation of the Anti-Drug Policy Department’s national early-warning system and reports forwarded by the EU Drugs Agency (EUDA). Researchers should verify the current status of any novel compound against the latest table updates before ordering.

In practice: Italian customs (Agenzia delle Dogane e dei Monopoli, ADM) generally treats goods moving within the EU customs union as intra-Community movements not subject to import duties or routine inspection. Restricted, mislabelled, or unlawful goods can still be stopped. Orders arriving from outside the EU may be examined and held, and ADM expressly screens for pharmaceuticals that do not comply with health legislation.

---

Why EU-Domestic Shipping Matters for Italian Researchers

Italy sits inside the EU single market and customs union. Suppliers with EU-based warehouses ship peptide orders without the customs delay, documentation burden, or seizure risk that affect shipments arriving from outside the EU. Typical delivery windows from EU warehouses to Italy:

• Western/Central EU (Romania, Slovakia, Czech Republic): 2–5 business days
• Northern EU (Baltic states): 3–6 business days
• UK-based suppliers: subject to EU import controls post-Brexit; 5–10+ days with variable customs outcomes

For time-sensitive research protocols or compounds that benefit from a short transit, EU-domestic shipping is strongly preferred.

---

How to Evaluate a Research Peptide Supplier: The COA Standard

A Certificate of Analysis (COA) is the central quality document in research peptide procurement. Its evidentiary value depends entirely on who produced it and how.

The minimum acceptable COA

An acceptable third-party COA for research-grade peptides must include:

• HPLC purity (%): High-Performance Liquid Chromatography with the chromatogram included. Purity should be 98% or higher for research-grade material; 99%+ is achievable and increasingly common among quality suppliers.
• Identity confirmation via LC-MS (Liquid Chromatography-Mass Spectrometry): the observed molecular mass must match the theoretical mass of the named peptide within standard instrument tolerance.
• Lot/batch number matching exactly what is printed on the vial. A COA from a different batch is not a COA for what was received.
• Testing laboratory name, address, and date. Independent labs issue reports on letterhead with contact information. Requests to “contact us for the COA” without a document are a red flag.
• No ownership link to the supply chain. The lab must not be owned by, operated by, or co-located with the manufacturer or vendor.

Janoshik Analytical: the EU research peptide reference lab

Janoshik Analytical (Prague, Czech Republic) has become the most widely used third-party testing laboratory for research peptides in the European market. Each of their reports shows the results measured on the sample it tested. Each Janoshik report we publish carries a task number that can be referenced in procurement documentation.

Extended COA parameters

Some EU suppliers now provide expanded COA packages: endotoxin testing (LAL assay), bioburden (microbial limit testing), heavy-metal screening (ICP-MS), and residual-solvent testing. These parameters matter for cell-culture and small-animal research where contamination artefacts could confound results. If your protocol is sensitivity-limited, request these extended parameters before ordering.

---

Sourcing Criteria Checklist for Italian Research Institutions

For researchers at Italian universities (Sapienza Università di Roma, Università di Bologna, Università di Milano, Università di Padova, Università di Napoli Federico II, Università di Torino), CNR institutes, or pharmaceutical and biotech companies ordering peptides for non-clinical studies, a standardised supplier-evaluation process reduces both quality risk and administrative overhead:

• COA on product page: independent third-party, correct lot number, HPLC + LC-MS minimum
• EU warehouse: confirmed EU-domestic shipping origin
• Delivery timeline documented: a stated SLA for Italy specifically, not a generic “EU” figure
• Packaging standard: lyophilised vials in sealed glass, shipped with temperature-appropriate packaging
• Reconstitution documentation, covering bacteriostatic water compatibility, storage temperature (typically −20°C long-term), and solubility notes (aqueous vs organic solvent)
• Legal compliance statement: “for research purposes only, not for human consumption” on product page and packaging
• Invoice/documentation: commercial invoice for institutional procurement records, VAT-compliant billing

---

What Italian Researchers Are Ordering in 2026

Research peptide classes commonly available to and studied by researchers sourcing from Italy in 2026 include:

Healing and tissue-biology research: BPC-157.

Metabolic and receptor-biology research: GLP-1 class compounds (semaglutide, tirzepatide, retatrutide) for receptor pharmacology, islet-cell biology, and adipocyte studies. Note: these require strict research-only framing in all procurement and lab documentation.

Longevity and telomere-biology research: Epitalon (tetrapeptide), GHK-Cu (copper peptide), MOTS-c (mitochondrial-derived peptide). Interest in this cluster has grown following several high-profile publications.

Nootropic and CNS research: Selank, Semax, Dihexa. Academic interest in these neuropeptides has picked up as source data from Eastern European research institutions becomes more accessible.

---

Storage and Handling for Research-Grade Peptides

Proper storage preserves peptide integrity and analytical validity. Standard protocols for lyophilised (freeze-dried) research peptides:

• Long-term storage: −20°C in the original sealed vial, protected from moisture and light
• Working aliquot (post-reconstitution): 4°C refrigerated, typically stable 2–4 weeks depending on the peptide
• Reconstitution vehicle: bacteriostatic water is standard for most peptides; 0.1% acetic acid is used for GH-releasing peptides (GHRP class) with poor aqueous solubility. Low-concentration dimethyl sulfoxide (DMSO) is used for select hydrophobic peptides, so confirm with the supplier’s reconstitution guide.
• Cycle count: minimise freeze-thaw cycles. Single-use aliquots are recommended for sensitive assays.

All storage notes above describe laboratory handling protocols for research compounds. They do not constitute instructions for human use.

---

Key Questions to Ask Any Supplier Before Ordering

1. Which independent laboratory performed the COA, and what was the lot number tested?
2. Can you provide the full COA document, rather than only the purity figure, before I place an order?
3. Where is your EU warehouse located, and what is the expected delivery time to [Italian city or postal code]?
4. Do you ship with cold-chain packaging for GLP-1 class peptides?
5. What is your re-test policy if a received vial shows evidence of degradation?
6. Is your packaging labelled for research purposes only, with no human-use language?

---

Summary

Italian researchers have access to a well-developed EU market for research-grade peptides. The legal picture is defined by the Codice del farmaco (Decreto Legislativo 219/2006, administered by AIFA) for medicinal products and the Testo Unico stupefacenti (DPR 309/1990) for controlled substances, with compliant research chemicals generally sitting outside both. The practical differentiators are COA quality (independent third-party, lot-matched, HPLC+MS minimum), EU-domestic shipping logistics, and strict research-only framing. Suppliers with transparent, publicly posted COAs and EU-based inventory are the appropriate starting point for institutional and academic procurement decisions.

CertaPeptides ships from within the EU to Italy, posts Janoshik reports for selected lots on the product pages, and labels all compounds for research purposes only. No human-use claims are made.

---

This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.

Regulatory & Legal Sources

Primary, authoritative references for the regulatory framework outlined above. These are official national and EU bodies; verify the current status of any specific compound directly with them before ordering. For research purposes only.

• AIFA — Agenzia Italiana del Farmaco (Italian medicines agency).
• Agenzia delle Dogane e dei Monopoli (ADM) — Italian customs.
• EUR-Lex — EU legal database (medicinal products and chemicals framework).
• European Medicines Agency (EMA) — EU-level authorisation and oversight of medicinal substances.

For laboratory research purposes only. Not for human consumption.

Researchers in Spain sourcing peptide compounds for in-vitro and preclinical studies are working in a market that shifted noticeably over the past year. The March 2026 closure of Peptide Sciences, one of the most-cited US benchmark suppliers, removed a common reference point for the research community and shifted demand toward EU-based alternatives that ship without customs delays. This guide covers what actually matters in that sourcing decision for Spain: the legal framework, COA standards, logistics, and the criteria that separate genuine research-grade suppliers from the rest.

---

Is It Legal to Buy Research Peptides in Spain?

Synthetic peptides sold as research chemicals sit at the intersection of two Spanish regulatory frameworks, and knowing which one applies is what makes sourcing compliant. The national authority for medicines is the AEMPS, the Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency of Medicines and Medical Devices), an autonomous agency under the Ministry of Health that oversees the quality, safety, and information of medicines and medical devices in Spain.

The medicines framework (Real Decreto Legislativo 1/2015). Spain’s consolidated medicines statute is the texto refundido de la Ley de garantías y uso racional de los medicamentos y productos sanitarios, approved by Real Decreto Legislativo 1/2015 of 24 July (consolidating the earlier Ley 29/2006), which defines and regulates medicinal products. Broadly, a substance becomes a medicinal product when it is presented as suitable for treating or preventing disease, or when it is administered to restore, correct, or modify a physiological function. A peptide sold exclusively for in-vitro research, labelled “not for human consumption” and carrying no therapeutic claims, generally falls outside that definition. Classification turns on presentation, composition, and intended use, so the label alone is not an automatic exemption. The same law restricts the supply of prescription medicines: Article 3.5 prohibits the sale of prescription-only medicines and medical devices by mail order or telematic (online) means. The AEMPS is the competent authority for authorising and supervising medicinal products in Spain.

The controlled-substances framework. Spain controls narcotics and psychotropic substances through a layered set of instruments: Ley 17/1967 on narcotic drugs (estupefacientes), which implements the 1961 UN Single Convention; Real Decreto 2829/1977, which regulates the manufacture, distribution, prescription, and dispensing of psychotropic substances (psicotrópicos); and Ley 4/2009 of 15 June on the control of drug precursors. These regimes apply to scheduled substances and their precursors. Standard research peptides such as BPC-157, TB-500, GHK-Cu, Epitalon, Selank, Ipamorelin, and most growth-hormone secretagogues are synthetic peptide compounds and generally fall outside these narcotics/psychotropics schedules. Use of any scheduled substance for scientific purposes is permitted only with specific administrative authorisation.

Two areas carry elevated risk:

GLP-1 class compounds. Semaglutide, tirzepatide, and liraglutide are authorised medicinal substances in Spain, dispensed on prescription, and they carry elevated regulatory and import scrutiny. The European Medicines Agency (EMA) and the Heads of Medicines Agencies network (HMA), of which the AEMPS is part, have warned about a sharp rise in illegal medicines marketed as GLP-1 analogues. Any framing that presents these compounds as therapeutic alternatives to prescription medicines brings them squarely under the medicines law and its advertising and distance-selling rules. Framing must stay strictly scientific, and researchers should confirm import and handling requirements through their own institution.

Novel compounds. The controlled-substances schedules are subject to update, and newer psychoactive compounds can be added. Researchers should verify the current status of any novel compound before ordering.

In practice: Spanish customs is administered by the Agencia Tributaria. Movements of goods between EU member states are intra-EU acquisitions, not imports, and are generally not subject to customs duties or routine inspection. Restricted, mislabelled, or unlawful goods can still be stopped, and statistical reporting (Intrastat) applies above certain thresholds. Orders arriving from outside the EU may be examined and held.

---

Why EU-Domestic Shipping Matters for Spanish Researchers

Spain sits inside the EU customs union and the single market. Suppliers with EU-based warehouses ship peptide orders as intra-EU movements, without the customs delay, documentation burden, or seizure risk that affect shipments arriving from outside the EU. Typical delivery windows from EU warehouses to mainland Spain:

• Western/Central EU (Romania, Slovakia, Czech Republic): 3–5 business days
• Northern EU (Baltic states): 4–6 business days
• UK-based suppliers: subject to EU import controls post-Brexit; 5–10+ days with variable customs outcomes

Note that the Canary Islands are part of the EU customs territory but lie outside the EU VAT area (a local indirect tax, IGIC, applies instead), while Ceuta and Melilla sit outside both the EU VAT area and the EU customs union. Shipments to these territories are therefore treated differently from mainland and Balearic deliveries and can attract customs formalities. For time-sensitive research protocols or compounds that benefit from a short transit, EU-domestic shipping to the mainland is strongly preferred.

---

How to Evaluate a Research Peptide Supplier: The COA Standard

A Certificate of Analysis (COA) is the central quality document in research peptide procurement. Its evidentiary value depends entirely on who produced it and how.

The minimum acceptable COA

An acceptable third-party COA for research-grade peptides must include:

• HPLC purity (%): High-Performance Liquid Chromatography with the chromatogram included. Purity should be 98% or higher for research-grade material; 99%+ is achievable and increasingly common among quality suppliers.
• Identity confirmation via LC-MS (Liquid Chromatography–Mass Spectrometry): the observed molecular mass must match the theoretical mass of the named peptide within standard instrument tolerance.
• Lot/batch number matching exactly what is printed on the vial. A COA from a different batch is not a COA for what was received.
• Testing laboratory name, address, and date. Independent labs issue reports on letterhead with contact information. Requests to “contact us for the COA” without a document are a red flag.
• No ownership link to the supply chain. The lab must not be owned by, operated by, or co-located with the manufacturer or vendor.

Janoshik Analytical: the EU research peptide reference lab

Janoshik Analytical (Czech Republic) has become the most widely used third-party testing laboratory for research peptides in the European market. Each of their reports shows the results measured on the sample it tested. Each Janoshik report we publish carries a task number that can be referenced in procurement documentation.

Extended COA parameters

Some EU suppliers now provide expanded COA packages: endotoxin testing (LAL assay), bioburden (microbial limit testing), heavy-metal screening (ICP-MS), and residual-solvent testing. These parameters matter for cell-culture and small-animal research where contamination artefacts could confound results. If your protocol is sensitivity-limited, request these extended parameters before ordering.

---

Sourcing Criteria Checklist for Spanish Research Institutions

For researchers at Spanish universities (Universidad Complutense de Madrid, Universidad de Barcelona, Universidad Autónoma de Madrid, Universidad de Valencia, Universidad de Granada), CSIC institutes, hospital research units, or pharmaceutical and biotech companies ordering peptides for non-clinical studies, a standardised supplier-evaluation process reduces both quality risk and administrative overhead:

• COA on product page: independent third-party, correct lot number, HPLC + LC-MS minimum
• EU warehouse: confirmed EU-domestic shipping origin
• Delivery timeline documented: a stated SLA for Spain specifically, not a generic “EU” figure
• Packaging standard: lyophilised vials in sealed glass, shipped with temperature-appropriate packaging
• Reconstitution documentation, covering bacteriostatic water compatibility, storage temperature (typically −20°C long-term), and solubility notes (aqueous vs organic solvent)
• Legal compliance statement: “for research purposes only, not for human consumption” on product page and packaging
• Invoice/documentation: commercial invoice for institutional procurement records, VAT-compliant billing

---

What Spanish Researchers Are Ordering in 2026

Research peptide classes commonly available to and studied by researchers sourcing from Spain in 2026 include:

Healing and tissue-biology research: BPC-157.

Metabolic and receptor-biology research: GLP-1 class compounds (semaglutide, tirzepatide, retatrutide) for receptor pharmacology, islet-cell biology, and adipocyte studies. Note: these are authorised medicinal substances and require strict research-only framing in all procurement and lab documentation.

Longevity and telomere-biology research: Epitalon (tetrapeptide), GHK-Cu (copper peptide), MOTS-c (mitochondrial-derived peptide). Interest in this cluster has grown following several high-profile publications.

Nootropic and CNS research: Selank, Semax, Dihexa. Academic interest in these neuropeptides has widened as source data from Eastern European research institutions becomes more accessible.

---

Storage and Handling for Research-Grade Peptides

Proper storage preserves peptide integrity and analytical validity. Standard protocols for lyophilised (freeze-dried) research peptides:

• Long-term storage: −20°C in the original sealed vial, protected from moisture and light
• Working aliquot (post-reconstitution): 4°C refrigerated, typically stable 2–4 weeks depending on the peptide
• Reconstitution vehicle: bacteriostatic water is standard for most peptides; 0.1% acetic acid is used for GH-releasing peptides (GHRP class) with poor aqueous solubility. Low-concentration dimethyl sulfoxide (DMSO) is used for select hydrophobic peptides, so confirm with the supplier’s reconstitution guide.
• Cycle count: minimise freeze-thaw cycles. Single-use aliquots are recommended for sensitive assays.

All storage notes above describe laboratory handling protocols for research compounds. They do not constitute instructions for human use.

---

Key Questions to Ask Any Supplier Before Ordering

1. Which independent laboratory performed the COA, and what was the lot number tested?
2. Can you provide the full COA document, rather than only the purity figure, before I place an order?
3. Where is your EU warehouse located, and what is the expected delivery time to [Spanish city or postal code]?
4. Do you ship with cold-chain packaging for GLP-1 class peptides?
5. What is your re-test policy if a received vial shows evidence of degradation?
6. Is your packaging labelled for research purposes only, with no human-use language?

---

Summary

Researchers in Spain have access to a well-developed EU market for research-grade peptides. The regulatory picture is anchored by the medicines framework, Real Decreto Legislativo 1/2015, supervised by the AEMPS, together with the controlled-substances regime (Ley 17/1967, Real Decreto 2829/1977, and Ley 4/2009 on precursors), under which compliant research chemicals that are neither medicinal products nor scheduled substances generally sit. The practical differentiators are COA quality (independent third-party, lot-matched, HPLC+MS minimum), EU-domestic shipping logistics, and strict research-only framing. Suppliers with transparent, publicly posted COAs and EU-based inventory are the appropriate starting point for institutional and academic procurement decisions.

CertaPeptides ships from within the EU to Spain, posts Janoshik reports for selected lots on the product pages, and labels all compounds for research purposes only. No human-use claims are made.

---

This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.

Regulatory & Legal Sources

Primary, authoritative references for the regulatory framework outlined above. These are official national and EU bodies; verify the current status of any specific compound directly with them before ordering. For research purposes only.

• AEMPS — Agencia Española de Medicamentos y Productos Sanitarios (Spanish national medicines authority).
• Boletín Oficial del Estado (BOE) — consolidated Spanish legislation, including Real Decreto Legislativo 1/2015.
• Agencia Tributaria — Spanish customs and intra-EU movement of goods.
• European Medicines Agency (EMA) — EU-level authorisation and oversight of medicinal substances.

For laboratory research purposes only. Not for human consumption. This article is general regulatory information, not legal advice; see the closing note. Last reviewed June 2026.

The Short Answer

Across most of Europe, sourcing a synthetic peptide strictly as a research chemical (labelled “not for human consumption,” carrying no therapeutic claims, and intended for laboratory use) may be lawful depending on the specific compound, the buyer, the intended use, and the national law that applies, because such a product can fall outside the EU definition of a “medicinal product.” This is not a blanket “yes”: legality is not uniform across Europe and has to be verified locally. The key high-risk category is GLP-1-class compounds such as semaglutide, tirzepatide, and liraglutide, which are active substances in separately authorised medicines and therefore attract far higher regulatory and customs scrutiny everywhere. There is no single Europe-wide license: the position depends on each country’s national medicines law, its controlled-substances list, and whether the shipment crosses an external EU customs border, so the precise status must be confirmed for your own jurisdiction and compound before ordering.

The table further down maps the baseline position country by country across all 27 EU member states plus the United Kingdom and Switzerland. The sections around it explain the shared EU framework that produces those positions, give deep, primary-sourced detail for five jurisdictions, and answer the most common country-specific questions.

---

The EU-Wide Framework: It Starts With the Definition of a “Medicine”

The single most important concept across the entire EU is how a substance becomes legally classified as a medicinal product. This is set by Directive 2001/83/EC, the Community code relating to medicinal products for human use, which every member state has transposed into national law. (consolidated text on EUR-Lex.)

Under Article 1(2) of the Directive, a substance is a medicinal product in either of two ways:

• By presentation: any substance “presented as having properties for treating or preventing disease in human beings.”
• By function: any substance that “may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.”

This two-limb test is the hinge on which research-chemical regulation turns. A synthetic peptide sold strictly as a research chemical, labelled “not for human consumption,” carrying no therapeutic claims, and intended for laboratory use, generally falls outside the presentation limb, because nothing about how it is presented suggests treating disease. That is precisely why research-only framing matters beyond marketing: a product marketed with disease claims or human-use instructions can be pulled into the medicinal-product definition by presentation alone, regardless of the molecule itself.

Two important caveats apply everywhere:

• The label is not an automatic exemption. Classification ultimately turns on presentation, composition, and intended use taken together. A “research use only” sticker does not override the substance’s actual characteristics, and a borderline product can still be assessed case-by-case by a national authority.
• The advertising rules are strict. Article 86 onward of the Directive governs the advertising of medicinal products, and Article 87 prohibits advertising a medicine that does not hold a marketing authorisation. This is the legal backbone behind the rule that research compounds must never be promoted with research protocols framed as human dosing, outcomes, or disease claims.

The GLP-1 exception: elevated scrutiny EU-wide

There is one class of compounds that warrants separate mention everywhere in Europe. Semaglutide, tirzepatide, and liraglutide are active substances in medicines that hold marketing authorisations across the EU and the UK. Because authorised medicines built on these substances already exist, anything that presents an unlicensed GLP-1 compound as an alternative to those medicines maps directly onto the medicinal-product definition and the advertising prohibition above. Regulators treat this class with markedly higher scrutiny than ordinary research chemicals, both as an advertising-compliance matter and as a customs and import matter, where shipments can be examined as potential unlicensed-medicine imports. For GLP-1-class compounds in particular, framing must stay strictly scientific and researchers should confirm import and handling requirements through their own institution. See also our explainer on the June 2026 EMA synthetic-peptide guideline.

---

Research Peptide Legal Status in Europe: Country-by-Country Table (2026)

The table below describes the general regulatory posture in each country: the national medicines authority that applies the EU framework above, whether the country has any known blanket ban on research chemicals, the customs/import note, and the prescription/GLP-1 note. It is a structural map, not an authoritative legality ruling on any specific transaction. Two rules run through every row: (1) a specific compound on a national controlled-substances list is a separate question that must be checked against that list, and (2) GLP-1-class compounds (semaglutide, tirzepatide, liraglutide) carry elevated scrutiny everywhere because they are active substances in authorised medicines. “EU-internal” in the import column means goods moving from inside the EU customs union to another EU destination are treated as internal-market shipments rather than imports; this does not legalise a restricted or unlawful good, it only describes the customs handling.

Descriptive summary only, not legal advice; confirm the current status with the named national authority before ordering. “No known blanket ban” means the country has no general prohibition on research chemicals as a class; it is not a ruling that any particular compound or purchase is lawful for you.

How to read this table: “No known blanket ban on research chemicals” describes the general regulatory posture, not a guarantee that any specific compound or transaction is lawful for you. Always cross-check the exact compound against your national controlled-substances list, and treat GLP-1-class compounds as the highest-scrutiny category. National medicines-authority names are given so you can go straight to the primary source and confirm the current status before ordering. If a shipment originates outside the EU or is bound for the UK or Switzerland, it crosses an external customs border and can be inspected; even intra-EU shipments of restricted goods can still be inspected. Our explainer on why research-peptide parcels get seized at EU customs covers what that looks like in practice.

---

Verified Jurisdiction Detail

The following five jurisdictions are covered in depth because their framework can be tied to a primary source. Each entry names the governing statute and the competent authority. None of this is a statement that any particular transaction is lawful; it is a description of the regulatory structure.

Germany: Arzneimittelgesetz (AMG)

Germany transposes the EU framework through the Arzneimittelgesetz (AMG, the Medicinal Products Act). Its § 2(1) defines a medicinal product in terms that mirror the Directive: substances intended for curing, alleviating, or preventing disease, or for restoring, correcting, or modifying physiological functions. The competent authority is the BfArM (Bundesinstitut fur Arzneimittel und Medizinprodukte, the Federal Institute for Drugs and Medical Devices). Controlled substances are governed separately under the Betaubungsmittelgesetz (BtMG, the Narcotics Act), and items falling under the BtMG face import restrictions. A peptide sold as a research chemical with no therapeutic presentation generally sits outside the AMG’s medicinal-product definition, but the classification is assessed on presentation and intended use, and Germany is a strong-enforcement jurisdiction, particularly for GLP-1-class compounds. Source: Medicinal Products Act (AMG), gesetze-im-internet.de; BfArM — Medicinal products.

Netherlands: Geneesmiddelenwet, Opiumwet, Warenwet

Dutch sourcing sits at the intersection of three laws. The Geneesmiddelenwet (Medicines Act) carries the medicinal-product definition and the medicines-advertising rules, enforced by the IGJ (Inspectie Gezondheidszorg en Jeugd) with the CBG-MEB as the licensing board. The Opiumwet (Opium Act) lists controlled substances on its List I and List II. Beyond those two, a research chemical that is neither a medicine nor on the Opiumwet lists is still subject to general chemical-product law, including EU REACH/CLP obligations and, depending on context, the Warenwet (Commodities Act) enforced by the NVWA. Rather than assume a single catch-all framework applies, verify the applicable national chemical and medicines law for the specific compound. Standard research peptides are not on the Opiumwet lists as of mid-2026, but novel compounds should be checked against the current lists, and a borderline product can still be assessed case-by-case. Source: verified against KNMP, Douane Kennisbank, IGJ, CBG-MEB, and business.gov.nl.

France: Code de la sante publique (ANSM)

France governs medicines through the Code de la sante publique (CSP). The medicinal-product definition sits at Article L.5111-1, mirroring the EU two-limb test. Controlled and poisonous substances are classified as stupefiants (narcotics) under the arrete du 22 fevrier 1990 and as substances veneneuses on Lists I and II under Article L.5132-6. The competent authority is the ANSM (Agence nationale de securite du medicament et des produits de sante), which since February 2022 also classifies controlled and poisonous substances. These lists are revised periodically by ANSM decision, so the current classification of any new or analogue compound should be confirmed before ordering. Source: verified against ANSM and Legifrance.

United Kingdom: MHRA (post-Brexit)

Since leaving the EU, the UK runs its own regime, with the MHRA (Medicines and Healthcare products Regulatory Agency) as the competent authority. The UK retained an equivalent medicinal-product definition and the prohibition on advertising unlicensed medicines. Two points are specific to the UK research-peptide context. First, the GLP-1 medicines semaglutide, tirzepatide, and liraglutide are licensed in the UK but are prescription-only; supplying them outside authorised channels (for example as unlicensed weight-loss products or research chemicals for human use) is illegal, while compounds such as BPC-157 hold no UK marketing authorisation. Second, the MHRA has been visibly active in enforcement: it has reported seizing counterfeit GLP-1 pens (including fake semaglutide pens) and has shut down an illegal facility manufacturing unlicensed GLP-1 products. Post-Brexit, UK-bound shipments are also subject to import controls that EU-internal movements are not. The UK is therefore a notably elevated-enforcement environment for GLP-1-class compounds. Sources: GOV.UK — MHRA Drug Safety Update on GLP-1 receptor agonists; Pharmaceutical Technology — MHRA shuts down illegal GLP-1RA facility.

Switzerland: Swissmedic (non-EU)

Switzerland is outside the EU and runs an independent system under the Therapeutic Products Act (Heilmittelgesetz, HMG, also the TPA), administered by Swissmedic, the Swiss Agency for Therapeutic Products. Medicinal products may only be distributed in Switzerland if authorised by Swissmedic, and the Act also governs licensing for manufacturing and wholesale trade, market surveillance, and advertising. Because Switzerland sits outside the EU customs union, inbound shipments cross a customs border and are not EU-internal movements. Researchers ordering into Switzerland should treat the Swissmedic framework, not EU rules, as the governing reference and confirm import requirements before ordering. Source: Swissmedic — Swiss Agency for Therapeutic Products.

---

Frequently Asked Questions

Are research peptides legal to buy in Europe?

It depends, and it is not a blanket “yes.” In most European countries, sourcing a synthetic peptide strictly as a research chemical (research-use-only, “not for human consumption,” no therapeutic claims) may be lawful depending on the specific compound, the buyer, the intended use, and national law, because such a product can fall outside the EU medicinal-product definition in Directive 2001/83/EC. It can be unlawful where the compound is on a national controlled-substances list, where it is a GLP-1-class compound (which carries elevated scrutiny everywhere), or where presentation or intended use pulls it into the medicinal-product definition. Always verify the current position for your specific country and compound with the national authority before ordering.

Is it legal to buy research peptides in Germany?

Germany applies the EU framework through the Arzneimittelgesetz (AMG), with BfArM as the medicines authority and the Betaubungsmittelgesetz (BtMG) governing controlled substances. A peptide sold as a research chemical with no therapeutic presentation can sit outside the AMG’s medicinal-product definition, but classification is assessed case-by-case on presentation and intended use, and Germany is a strong-enforcement jurisdiction, especially for GLP-1-class compounds. Check the specific compound against the BtMG and confirm the position before ordering.

Is it legal to buy research peptides in France?

France governs medicines through the Code de la sante publique, with ANSM as the competent authority. Standard research peptides sold research-use-only can fall outside the medicinal-product definition, but ANSM also classifies controlled and poisonous substances (stupefiants and substances veneneuses Lists I and II), and these lists are revised periodically, so confirm the current classification of your compound first.

Is it legal to buy research peptides in the Netherlands?

Dutch rules sit across several layers: the Geneesmiddelenwet (Medicines Act), the Opiumwet (Opium Act) controlled-substances lists, and general chemical-product law (including EU REACH/CLP obligations). Rather than assume a single framework governs, verify the applicable national chemical and medicines law for your specific compound. Standard research peptides are not on the Opiumwet lists as of mid-2026, but novel compounds should be checked against the current lists, and the medicines authority can still assess a borderline product case-by-case before ordering.

Is it legal to buy research peptides in the UK?

Since Brexit, the UK runs its own regime under the MHRA and retained an equivalent medicinal-product definition. Research-use-only peptides can sit outside that definition, but the MHRA assesses products case-by-case and may disregard a “research use only” label where the product is in fact handled or marketed in a way that evades medicines rules. GLP-1 medicines (semaglutide, tirzepatide, liraglutide) are licensed and prescription-only, and supplying them outside authorised channels is illegal. UK-bound shipments also cross an external customs border and face import controls. The UK is an elevated-enforcement environment for GLP-1-class compounds.

Is it legal to import research peptides into Switzerland?

Switzerland is outside the EU and runs an independent system under the Therapeutic Products Act, administered by Swissmedic. Inbound shipments cross a customs border rather than moving EU-internally, so researchers should treat the Swissmedic framework as the governing reference and confirm import requirements before ordering.

Why are GLP-1 peptides treated differently across Europe?

Semaglutide, tirzepatide, and liraglutide are active substances in medicines that hold marketing authorisations across the EU and the UK. Because authorised medicines already exist, presenting an unlicensed GLP-1 compound as an alternative maps directly onto the medicinal-product definition and the advertising prohibition, so regulators apply markedly higher scrutiny as both an advertising-compliance and a customs matter.

How does customs handling differ for intra-EU shipments versus imports?

Shipments moving from inside the EU customs union to another EU destination are treated as internal-market movements rather than imports, so they avoid the customs import formalities that apply to shipments arriving from outside the EU or bound for non-EU states such as the UK and Switzerland. This does not legalise a restricted or unlawful good, and it does not make a parcel immune from inspection: restricted goods can still be inspected and controlled even on intra-EU movements. It only describes the customs handling. For background, see our guide on why research-peptide parcels get seized at EU customs.

---

Every Other Detail: How to Check Your Own Jurisdiction

The table gives the baseline; for the exact, current position on a specific compound, confirm it against primary sources. The same EU framework applies as a baseline in every EU member state; what differs is the national implementing statute, the controlled-substances list, and the enforcement body.

1. Identify your national medicines authority. Every EU member state has one (named in the table above), plus the EMA at EU level. This authority publishes the national transposition of Directive 2001/83/EC and the medicines-advertising rules.
2. Check your national controlled-substances list. Each country maintains its own narcotics/psychotropics schedule. Confirm whether the specific compound you intend to order appears on it, and re-check, because these lists are updated.
3. Confirm the customs position for your country. Within the EU customs union, intra-EU movements are generally treated as internal-market shipments rather than imports; shipments arriving from outside the EU (or into non-EU states such as Switzerland and the UK) cross a customs border and can be examined. Customs treatment is separate from the advertising/classification question.
4. Apply extra caution to GLP-1-class compounds. Wherever you are, semaglutide, tirzepatide, and liraglutide carry the elevated scrutiny described above.
5. Ask your institution. University legal/compliance offices, research-procurement teams, and institutional safety officers can confirm the rules that apply to your specific setting, which is often the fastest authoritative answer.

When a source disagrees with a forum post or a vendor’s marketing copy, trust the primary source (the statute or the authority’s own website) over the secondary commentary.

---

What This Means for Sourcing Decisions

The regulatory picture has a few practical consequences that hold across Europe:

• Research-only framing is structural, not cosmetic. Because classification can turn on presentation, a supplier that markets compounds with disease claims, human-use instructions, or outcome promises raises the regulatory profile of the entire transaction. Suppliers that keep strictly to research framing and “not for human consumption” labelling are the appropriate starting point.
• EU-internal shipping avoids a customs border. Suppliers shipping from within the EU customs union move goods as internal-market shipments to other EU destinations, without the customs import formalities that apply to shipments arriving from outside the EU or into non-EU states, though restricted or unlawful goods can still be controlled.
• GLP-1-class compounds sit in a category of their own. Treat semaglutide, tirzepatide, and liraglutide as the highest-scrutiny class for both advertising compliance and customs.
• Documentation supports compliance. A clear Certificate of Analysis, research-use-only labelling, and a proper commercial invoice make the research nature of a purchase legible to an institution’s procurement and compliance records.

---

Summary

Europe shares a common foundation, the medicinal-product definition by presentation or function in Directive 2001/83/EC together with the prohibition on advertising unlicensed medicines, but the detail lives in national law. The table above describes the general regulatory posture across all 27 EU member states plus the UK and Switzerland as a descriptive summary, not a legality ruling, and we have given primary-sourced detail for Germany (AMG, BfArM, BtMG), the Netherlands (Geneesmiddelenwet, Opiumwet, Warenwet), France (Code de la sante publique, ANSM), the UK (MHRA, post-Brexit, active GLP-1 enforcement), and Switzerland (Swissmedic, Therapeutic Products Act, non-EU). For any specific compound, the right move is to confirm it against your national medicines authority and controlled-substances list directly rather than rely on a blanket claim. And everywhere, GLP-1-class compounds warrant the most caution.

This is general regulatory information, not legal advice. Regulations and controlled-substances lists change, national rules differ in their detail, and individual circumstances vary. Before ordering, confirm the current position for your specific jurisdiction and use case with your institution’s compliance/legal office or with qualified local counsel.

CertaPeptides is a reseller: we supply research compounds sourced from suppliers, ship from within the EU, and label all compounds for research use only. For tested batches we publish independent third-party Janoshik reports; look for the COA/Verify badge on the product. No human-use claims are made.

---

This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.

{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “Are research peptides legal to buy in Europe?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “It depends, and it is not a blanket yes. In most European countries, sourcing a synthetic peptide strictly as a research chemical (research-use-only, not for human consumption, no therapeutic claims) may be lawful depending on the specific compound, the buyer, the intended use, and national law, because such a product can fall outside the EU medicinal-product definition in Directive 2001/83/EC. It can be unlawful where the compound is on a national controlled-substances list, where it is a GLP-1-class compound, or where presentation or intended use pulls it into the medicinal-product definition. Always verify the current position for your specific country and compound with the national authority before ordering. This is descriptive information, not legal advice.”
}
},
{
“@type”: “Question”,
“name”: “Is it legal to buy research peptides in Germany?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Germany applies the EU framework through the Arzneimittelgesetz (AMG), with BfArM as the medicines authority and the Betaubungsmittelgesetz (BtMG) governing controlled substances. A peptide sold as a research chemical with no therapeutic presentation can sit outside the AMG medicinal-product definition, but classification is assessed case-by-case, and Germany is a strong-enforcement jurisdiction, especially for GLP-1-class compounds. Check the specific compound against the BtMG and confirm the position before ordering. Descriptive information, not legal advice.”
}
},
{
“@type”: “Question”,
“name”: “Is it legal to buy research peptides in France?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “France governs medicines through the Code de la sante publique, with ANSM as the competent authority. Standard research peptides sold research-use-only can fall outside the medicinal-product definition, but ANSM also classifies controlled and poisonous substances (stupefiants and substances veneneuses Lists I and II), and these lists are revised periodically, so confirm the current classification of your compound first. Descriptive information, not legal advice.”
}
},
{
“@type”: “Question”,
“name”: “Is it legal to buy research peptides in the Netherlands?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Dutch rules sit across several layers: the Geneesmiddelenwet (Medicines Act), the Opiumwet (Opium Act) controlled-substances lists, and general chemical-product law including EU REACH/CLP obligations. Rather than assume a single framework governs, verify the applicable national chemical and medicines law for your specific compound. Standard research peptides are not on the Opiumwet lists as of mid-2026, but novel compounds should be checked against the current lists, and a borderline product can still be assessed case-by-case before ordering. Descriptive information, not legal advice.”
}
},
{
“@type”: “Question”,
“name”: “Is it legal to buy research peptides in the UK?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Since Brexit, the UK runs its own regime under the MHRA and retained an equivalent medicinal-product definition. Research-use-only peptides can sit outside that definition, but the MHRA assesses products case-by-case and may disregard a research-use-only label where the product is in fact handled or marketed in a way that evades medicines rules. GLP-1 medicines (semaglutide, tirzepatide, liraglutide) are licensed and prescription-only, and supplying them outside authorised channels is illegal. UK-bound shipments cross an external customs border and face import controls. The UK is an elevated-enforcement environment for GLP-1-class compounds. Descriptive information, not legal advice.”
}
},
{
“@type”: “Question”,
“name”: “Is it legal to import research peptides into Switzerland?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Switzerland is outside the EU and runs an independent system under the Therapeutic Products Act, administered by Swissmedic. Inbound shipments cross a customs border rather than moving EU-internally, so researchers should treat the Swissmedic framework as the governing reference and confirm import requirements before ordering. Descriptive information, not legal advice.”
}
},
{
“@type”: “Question”,
“name”: “Why are GLP-1 peptides treated differently across Europe?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Semaglutide, tirzepatide, and liraglutide are active substances in medicines that hold marketing authorisations across the EU and the UK. Because authorised medicines already exist, presenting an unlicensed GLP-1 compound as an alternative maps directly onto the medicinal-product definition and the advertising prohibition, so regulators apply markedly higher scrutiny as both an advertising-compliance and a customs matter.”
}
},
{
“@type”: “Question”,
“name”: “How does customs handling differ for intra-EU shipments versus imports?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Shipments moving from inside the EU customs union to another EU destination are treated as internal-market movements rather than imports, so they avoid the customs import formalities that apply to shipments arriving from outside the EU or bound for non-EU states such as the UK and Switzerland. This does not legalise a restricted or unlawful good, and it does not make a parcel immune from inspection: restricted goods can still be inspected and controlled even on intra-EU movements. It only describes the customs handling.”
}
}
]
}

For laboratory research purposes only. Not for human consumption.

Dutch researchers sourcing peptide compounds for in-vitro and preclinical studies are working in a market that shifted noticeably over the past year. The March 2026 closure of Peptide Sciences, one of the most-cited US benchmark suppliers, removed a common reference point for the research community and pushed demand toward EU-based alternatives that ship without customs delays. This guide covers what actually matters in that sourcing decision for the Netherlands: the legal framework, COA standards, logistics, and the criteria that separate genuine research-grade suppliers from the rest.

---

Is It Legal to Buy Research Peptides in the Netherlands?

Synthetic peptides sold as research chemicals sit at the intersection of three Dutch laws, and knowing which one applies is what makes sourcing compliant.

The Geneesmiddelenwet (Medicines Act). This act defines when a substance is a medicinal product: broadly, when it is presented as suitable for treating or preventing disease, or when it is administered to restore, correct, or modify a physiological function. A peptide sold exclusively for in-vitro research, labelled “not for human consumption” and carrying no therapeutic claims, generally falls outside that definition. Classification ultimately turns on presentation, composition, and intended use, so the label alone is not an automatic exemption. The Geneesmiddelenwet also governs medicines advertising, enforced by the IGJ (Inspectie Gezondheidszorg en Jeugd) with the CBG-MEB (Medicines Evaluation Board) as the licensing authority.

The Opiumwet (Opium Act). This prohibits substances on its List I (hard drugs) and List II (soft drugs). Standard research peptides, including BPC-157, TB-500, GHK-Cu, Epitalon, Selank, Ipamorelin, and most growth hormone secretagogues, do not appear on either list as of mid-2026. Use of listed substances for scientific purposes is permitted only with specific administrative authorisation, but that regime does not reach unlisted research peptides.

The Warenwet (Commodities Act). Research chemicals that are not medicines and not on the Opiumwet lists, sold as research material with “not for human consumption” labelling, typically fall under the Warenwet (the Dutch commodities framework, enforced by the NVWA). Depending on the substance they may also implicate EU CLP and REACH chemical-safety rules. This is the category most quality research peptides occupy.

Two areas carry elevated risk:

GLP-1 class compounds. Semaglutide, tirzepatide, and liraglutide are authorised medicinal products in the Netherlands and carry elevated regulatory and import scrutiny. Any framing that presents them as therapeutic alternatives to prescription medicines brings them under the Geneesmiddelenwet and its advertising rules, which the IGJ actively enforces. Framing must stay strictly scientific, and researchers should confirm import and handling requirements through their own institution.

Novel compounds. The Opiumwet lists are subject to update, and newer psychoactive compounds can be added. Researchers should verify the current status of any novel compound before ordering.

In practice: Dutch customs (Douane) generally treats small-quantity research-chemical shipments from within the EU as internal-market movements not subject to import duties or routine inspection. Restricted, mislabelled, or unlawful goods can still be stopped, and orders from outside the EU may be examined and held.

---

Why EU-Domestic Shipping Matters for Dutch Researchers

The Netherlands sits inside the EU single market and customs union. Suppliers with EU-based warehouses ship peptide orders without the customs delay, documentation burden, or seizure risk that affect shipments arriving from outside the EU. Typical delivery windows from EU warehouses to the Netherlands:

• Western/Central EU (Romania, Slovakia, Czech Republic): 2–4 business days
• Northern EU (Baltic states): 3–5 business days
• UK-based suppliers: subject to EU import controls post-Brexit; 5–10+ days with variable customs outcomes

For time-sensitive research protocols or compounds that benefit from a short transit, EU-domestic shipping is strongly preferred.

---

How to Evaluate a Research Peptide Supplier: The COA Standard

A Certificate of Analysis (COA) is the central quality document in research peptide procurement. Its evidentiary value depends entirely on who produced it and how.

The minimum acceptable COA

An acceptable third-party COA for research-grade peptides must include:

• HPLC purity (%): High-Performance Liquid Chromatography with the chromatogram included. Purity should be 98% or higher for research-grade material; 99%+ is achievable and increasingly common among quality suppliers.
• Identity confirmation via LC-MS (Liquid Chromatography-Mass Spectrometry): the observed molecular mass must match the theoretical mass of the named peptide within standard instrument tolerance.
• Lot/batch number matching exactly what is printed on the vial. A COA from a different batch is not a COA for what was received.
• Testing laboratory name, address, and date. Independent labs issue reports on letterhead with contact information. Requests to “contact us for the COA” without a document are a red flag.
• No ownership link to the supply chain. The lab must not be owned by, operated by, or co-located with the manufacturer or vendor.

Janoshik Analytical: the EU research peptide reference lab

Janoshik Analytical (Czech Republic) has become the most widely used third-party testing laboratory for research peptides in the European market. Each of their reports shows the results measured on the sample it tested. Each Janoshik report we publish carries a task number that can be referenced in procurement documentation.

Extended COA parameters

Some EU suppliers now provide expanded COA packages: endotoxin testing (LAL assay), bioburden (microbial limit testing), heavy-metal screening (ICP-MS), and residual-solvent testing. These parameters matter for cell-culture and small-animal research where contamination artefacts could confound results. If your protocol is sensitivity-limited, request these extended parameters before ordering.

---

Sourcing Criteria Checklist for Dutch Research Institutions

For researchers at Dutch universities (TU Delft, Utrecht, Leiden, Amsterdam UMC, Erasmus MC, Groningen), TNO, or pharmaceutical companies ordering peptides for non-clinical studies, a standardised supplier-evaluation process reduces both quality risk and administrative overhead:

• COA on product page: independent third-party, correct lot number, HPLC + LC-MS minimum
• EU warehouse: confirmed EU-domestic shipping origin
• Delivery timeline documented: a stated SLA for the Netherlands specifically, not a generic “EU” figure
• Packaging standard: lyophilised vials in sealed glass, shipped with temperature-appropriate packaging
• Reconstitution documentation, covering bacteriostatic water compatibility, storage temperature (typically −20°C long-term), and solubility notes (aqueous vs organic solvent)
• Legal compliance statement: “for research purposes only, not for human consumption” on product page and packaging
• Invoice/documentation: commercial invoice for institutional procurement records, VAT-compliant billing

---

What Dutch Researchers Are Ordering in 2026

Research peptide classes commonly available to and studied by researchers sourcing from the Netherlands in 2026 include:

Healing and tissue-biology research: BPC-157.

Metabolic and receptor-biology research: GLP-1 class compounds (semaglutide, tirzepatide, retatrutide) for receptor pharmacology, islet-cell biology, and adipocyte studies. Note: these require strict research-only framing in all procurement and lab documentation.

Longevity and telomere-biology research: Epitalon (tetrapeptide), GHK-Cu (copper peptide), MOTS-c (mitochondrial-derived peptide). Interest in this cluster has grown following several high-profile publications.

Nootropic and CNS research: Selank, Semax, Dihexa. Academic interest in these neuropeptides has risen as source data from Eastern European research institutions becomes more accessible.

---

Storage and Handling for Research-Grade Peptides

Proper storage preserves peptide integrity and analytical validity. Standard protocols for lyophilised (freeze-dried) research peptides:

• Long-term storage: −20°C in the original sealed vial, protected from moisture and light
• Working aliquot (post-reconstitution): 4°C refrigerated, typically stable 2–4 weeks depending on the peptide
• Reconstitution vehicle: bacteriostatic water is standard for most peptides; 0.1% acetic acid is used for GH-releasing peptides (GHRP class) with poor aqueous solubility. Low-concentration dimethyl sulfoxide (DMSO) is used for select hydrophobic peptides, so confirm with the supplier’s reconstitution guide.
• Cycle count: minimise freeze-thaw cycles. Single-use aliquots are recommended for sensitive assays.

All storage notes above describe laboratory handling protocols for research compounds. They do not constitute instructions for human use.

---

Key Questions to Ask Any Supplier Before Ordering

1. Which independent laboratory performed the COA, and what was the lot number tested?
2. Can you provide the full COA document, rather than only the purity figure, before I place an order?
3. Where is your EU warehouse located, and what is the expected delivery time to [Dutch city or postal code]?
4. Do you ship with cold-chain packaging for GLP-1 class peptides?
5. What is your re-test policy if a received vial shows evidence of degradation?
6. Is your packaging labelled for research purposes only, with no human-use language?

---

Summary

Dutch researchers have access to a well-developed EU market for research-grade peptides. The legal picture is defined by three laws: the Geneesmiddelenwet (medicines), the Opiumwet (controlled substances), and the Warenwet (commodities, where compliant research chemicals sit). In practice the differentiators are COA quality (independent third-party, lot-matched, HPLC+MS minimum), EU-domestic shipping logistics, and strict research-only framing. Suppliers with transparent, publicly posted COAs and EU-based inventory are the appropriate starting point for institutional and academic procurement decisions.

CertaPeptides ships from within the EU to the Netherlands, posts Janoshik reports for selected lots on the product pages, and labels all compounds for research purposes only. No human-use claims are made.

---

This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.

Regulatory & Legal Sources

Primary, authoritative references for the regulatory framework outlined above. These are official national and EU bodies; verify the current status of any specific compound directly with them before ordering. For research purposes only.

• CBG-MEB — Medicines Evaluation Board.
• wetten.overheid.nl — consolidated Dutch legislation, including the Geneesmiddelenwet.
• Douane — Dutch customs.
• European Medicines Agency (EMA) — EU-level authorisation and oversight of medicinal substances.

For laboratory research purposes only. Not for human consumption.

French researchers sourcing peptide compounds for in-vitro and preclinical studies are operating in a market that changed materially over the past year. When Peptide Sciences, one of the most-cited US benchmark suppliers, closed in March 2026, the research community lost a common reference point, and demand moved toward EU-based alternatives that ship without customs delays. This guide covers what matters in that sourcing decision for France: the legal framework, COA standards, logistics, and the criteria that separate genuine research-grade suppliers from the rest.

---

Is It Legal to Buy Research Peptides in France?

Synthetic peptides sold as research chemicals occupy a defined but qualified space in French law, governed primarily by the Code de la santé publique (CSP).

The medicinal-product definition (Art. L.5111-1 CSP). A substance is a medicinal product (médicament) when it is presented as having properties for treating or preventing disease in humans or animals, or when it is administered to restore, correct, or modify physiological functions. A peptide sold exclusively for in-vitro research, labelled “not for human consumption” and carrying no therapeutic claims, generally falls outside that definition. Classification ultimately turns on presentation, composition, and intended use, so the label alone is not an automatic exemption. Medicines and their advertising are overseen by the ANSM (Agence nationale de sécurité du médicament et des produits de santé), which since February 2022 is also the competent authority for classifying controlled and poisonous substances.

Controlled and poisonous substances (Art. L.5132-6 CSP; arrêté du 22 février 1990). France classifies substances as stupéfiants (narcotics) or as substances vénéneuses on Lists I and II. Standard research peptides such as BPC-157, TB-500, GHK-Cu, Epitalon, Selank, Ipamorelin, and most growth hormone secretagogues do not appear on the stupéfiants list or on Lists I/II as of mid-2026. The ANSM updates these lists periodically, so the current status of any novel compound should be verified before ordering.

Two areas carry elevated risk:

GLP-1 class compounds. Semaglutide, tirzepatide, and liraglutide are authorised medicinal products in France and carry elevated regulatory and import scrutiny. Any framing that presents them as therapeutic alternatives to prescription medicines brings them within the médicament definition and the CSP’s medicines-advertising rules, which the ANSM actively enforces. Framing must stay strictly scientific, and researchers should confirm import and handling requirements through their own institution.

Novel compounds. Because the stupéfiants and substances-vénéneuses lists are revised by ANSM decision (the arrêté du 22 février 1990 is amended regularly), researchers should confirm the current classification of any new or analogue compound before ordering.

In practice: French customs (la Douane) generally treats small-quantity research-chemical shipments from within the EU as internal-market movements not subject to import duties or routine inspection. Restricted, mislabelled, or unlawful goods can still be stopped, and orders from outside the EU may be examined and held.

---

Why EU-Domestic Shipping Matters for French Researchers

France is part of the EU single market and customs union. Suppliers with EU-based warehouses ship peptide orders without the customs delay, documentation burden, or seizure risk that affect shipments arriving from outside the EU. Typical delivery windows from EU warehouses to France:

• Western/Central EU (Romania, Slovakia, Czech Republic): 2–4 business days
• Northern EU (Baltic states): 3–5 business days
• UK-based suppliers: subject to EU import controls post-Brexit; 5–10+ days with variable customs outcomes

For time-sensitive research protocols or compounds that benefit from a short transit, EU-domestic shipping is strongly preferred.

---

How to Evaluate a Research Peptide Supplier: The COA Standard

The Certificate of Analysis (COA) is the central quality document in research peptide procurement. Its evidentiary value depends entirely on who produced it and how.

The minimum acceptable COA

An acceptable third-party COA for research-grade peptides must include:

• HPLC purity (%): High-Performance Liquid Chromatography with the chromatogram included. Purity should be 98% or higher for research-grade material; 99%+ is achievable and increasingly common among quality suppliers.
• Identity confirmation via LC-MS (Liquid Chromatography-Mass Spectrometry): the observed molecular mass must match the theoretical mass of the named peptide within standard instrument tolerance.
• Lot/batch number matching exactly what is printed on the vial. A COA from a different batch is not a COA for what was received.
• Testing laboratory name, address, and date. Independent labs issue reports on letterhead with contact information. Requests to “contact us for the COA” without a document are a red flag.
• No ownership link to the supply chain. The lab must not be owned by, operated by, or co-located with the manufacturer or vendor.

Janoshik Analytical: the EU research peptide reference lab

Janoshik Analytical (Czech Republic) has become the most widely used third-party testing laboratory for research peptides in the European market. Each of their reports shows the results measured on the sample it tested. Each Janoshik report we publish carries a task number that can be referenced in procurement documentation.

Extended COA parameters

Some EU suppliers now provide expanded COA packages: endotoxin testing (LAL assay), bioburden (microbial limit testing), heavy-metal screening (ICP-MS), and residual-solvent testing. These parameters matter for cell-culture and small-animal research where contamination artefacts could confound results. If your protocol is sensitivity-limited, request these extended parameters before ordering.

---

Sourcing Criteria Checklist for French Research Institutions

For researchers at French institutions (CNRS, INSERM, Institut Pasteur, CEA) and universities (Sorbonne Université, Université Paris-Saclay, Aix-Marseille) ordering peptides for non-clinical studies, a standardised supplier-evaluation process reduces both quality risk and administrative overhead:

• COA on product page: independent third-party, correct lot number, HPLC + LC-MS minimum
• EU warehouse: confirmed EU-domestic shipping origin
• Delivery timeline documented: a stated SLA for France specifically, not a generic “EU” figure
• Packaging standard: lyophilised vials in sealed glass, shipped with temperature-appropriate packaging
• Reconstitution documentation, covering bacteriostatic water compatibility, storage temperature (typically −20°C long-term), and solubility notes (aqueous vs organic solvent)
• Legal compliance statement: “for research purposes only, not for human consumption” on product page and packaging
• Invoice/documentation: commercial invoice for institutional procurement records, VAT-compliant billing

---

What French Researchers Are Ordering in 2026

Research peptide classes commonly available to and studied by researchers sourcing from France in 2026 include:

Healing and tissue-biology research: BPC-157.

Metabolic and receptor-biology research: GLP-1 class compounds (semaglutide, tirzepatide, retatrutide) for receptor pharmacology, islet-cell biology, and adipocyte studies. Note: these require strict research-only framing in all procurement and lab documentation.

Longevity and telomere-biology research: Epitalon (tetrapeptide), GHK-Cu (copper peptide), MOTS-c (mitochondrial-derived peptide). Interest in this cluster has grown following several high-profile publications.

Nootropic and CNS research: Selank, Semax, Dihexa. These neuropeptides have drawn more academic attention as source data from Eastern European research institutions becomes more accessible.

---

Storage and Handling for Research-Grade Peptides

Proper storage preserves peptide integrity and analytical validity. Standard protocols for lyophilised (freeze-dried) research peptides:

• Long-term storage: −20°C in the original sealed vial, protected from moisture and light
• Working aliquot (post-reconstitution): 4°C refrigerated, typically stable 2–4 weeks depending on the peptide
• Reconstitution vehicle: bacteriostatic water is standard for most peptides; 0.1% acetic acid is used for GH-releasing peptides (GHRP class) with poor aqueous solubility. Low-concentration dimethyl sulfoxide (DMSO) is used for select hydrophobic peptides, so confirm with the supplier’s reconstitution guide.
• Cycle count: minimise freeze-thaw cycles. Single-use aliquots are recommended for sensitive assays.

All storage notes above describe laboratory handling protocols for research compounds. They do not constitute instructions for human use.

---

Key Questions to Ask Any Supplier Before Ordering

1. Which independent laboratory performed the COA, and what was the lot number tested?
2. Can you provide the full COA document, rather than only the purity figure, before I place an order?
3. Where is your EU warehouse located, and what is the expected delivery time to [French city or postal code]?
4. Do you ship with cold-chain packaging for GLP-1 class peptides?
5. What is your re-test policy if a received vial shows evidence of degradation?
6. Is your packaging labelled for research purposes only, with no human-use language?

---

Summary

French researchers have access to a well-developed EU market for research-grade peptides. The legal picture is set by the Code de la santé publique: the médicament definition, the substances-vénéneuses Lists I/II, and the stupéfiants list, all overseen by the ANSM. In practice the differentiators are COA quality (independent third-party, lot-matched, HPLC+MS minimum), EU-domestic shipping logistics, and strict research-only framing. Suppliers with transparent, publicly posted COAs and EU-based inventory are the appropriate starting point for institutional and academic procurement decisions.

CertaPeptides ships from within the EU to France, posts Janoshik reports for selected lots on the product pages, and labels all compounds for research purposes only. No human-use claims are made.

---

This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.

Regulatory & Legal Sources

Primary, authoritative references for the regulatory framework outlined above. These are official national and EU bodies; verify the current status of any specific compound directly with them before ordering. For research purposes only.

• ANSM — Agence nationale de sécurité du médicament et des produits de santé.
• Douane française — French customs.
• EUR-Lex — EU legal database (framework reflected in the Code de la santé publique).
• European Medicines Agency (EMA) — EU-level authorisation and oversight of medicinal substances.